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ABSTRACT
Background Polypharmacy interventions are resource- 
intensive and should be targeted to those at risk of 
negative health outcomes. Our aim was to develop and 
internally validate prognostic models to predict health- 
related quality of life (HRQoL) and the combined outcome 
of falls, hospitalisation, institutionalisation and nursing 
care needs, in older patients with multimorbidity and 
polypharmacy in general practices.
Methods Design: two independent data sets, one 
comprising health insurance claims data (n=592 456), 
the other data from the PRIoritising MUltimedication in 
Multimorbidity (PRIMUM) cluster randomised controlled 
trial (n=502). Population: ≥60 years, ≥5 drugs, ≥3 chronic 
diseases, excluding dementia. Outcomes: combined 
outcome of falls, hospitalisation, institutionalisation and 
nursing care needs (after 6, 9 and 24 months) (claims 
data); and HRQoL (after 6 and 9 months) (trial data). 
Predictor variables in both data sets: age, sex, morbidity- 
related variables (disease count), medication- related 
variables (European Union- Potentially Inappropriate 
Medication list (EU- PIM list)) and health service utilisation. 
Predictor variables exclusively in trial data: additional 
socio- demographics, morbidity- related variables 
(Cumulative Illness Rating Scale, depression), Medication 
Appropriateness Index (MAI), lifestyle, functional status and 
HRQoL (EuroQol EQ- 5D- 3L). Analysis: mixed regression 
models, combined with stepwise variable selection, 10- 
fold cross validation and sensitivity analyses.
Results Most important predictors of EQ- 5D- 3L at 6 
months in best model (Nagelkerke’s R² 0.507) were 
depressive symptoms (−2.73 (95% CI: −3.56 to −1.91)), 
MAI (−0.39 (95% CI: −0.7 to −0.08)), baseline EQ- 5D- 3L 
(0.55 (95% CI: 0.47 to 0.64)). Models based on claims data 
and those predicting long- term outcomes based on both 
data sets produced low R² values. In claims data- based 
model with highest explanatory power (R²=0.16), previous 
falls/fall- related injuries, previous hospitalisations, age, 
number of involved physicians and disease count were 
most important predictor variables.
Conclusions Best trial data- based model predicted 
HRQoL after 6 months well and included parameters of 
well- being not found in claims. Performance of claims 
data- based models and models predicting long- term 
outcomes was relatively weak. For generalisability, future 
studies should refit models by considering parameters 
representing well- being and functional status.
BACKGROUND
Currently, up to 80% of primary care consul-
tations involve patients with multiple chronic 
conditions (multimorbidity).1 A multiplicity 
of disorders in patients is associated with 
polypharmacy. Both multimorbidity and 
polypharmacy are recognised as a major 
challenge facing healthcare systems.2–5 Poly-
pharmacy can increase the risk of mortality, 
hospitalisation6 7 and falls and fall- related 
injuries with resulting disability and loss of 
autonomy.8 9 It can also reduce cognitive and 
Strengths and limitations of this study
 ► We developed our predictive models using two com-
pletely different data sets—claims data and data 
primarily collected in a cluster- randomised trial.
 ► The claims data contained a large number of cases, 
enabling our models to include many possible pre-
dictors without any convergence issues.
 ► The trial data provided a rich set of potential pre-
dictor variables of high data quality and included 
data on patient- reported outcome measures, such 
as well- being and functional status.
 ► Both data sets have their own methodological lim-
itations, such as imprecise claims data (collected 
for reimbursement purposes) and the trial’s small 
sample size.
 ► The nature of the data meant neither data set could 
be used to validate a predictive model based on the 
other.
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physical function, as well as health- related quality of life 
(HRQoL).2 10
The number of drugs increases the probability of adverse 
drug reactions, but the relationship is inconsistent, 
suggesting that the number of medications alone may not 
adequately indicate the quality of an individual’s medica-
tion regimen.11 12 The kind of drugs prescribed plays an 
important role in the type of reaction, with certain medi-
cation classes, such as benzodiazepines, demonstrating 
a significant association with falls, and medications 
with anti- cholinergic properties being associated with 
impaired cognitive and physical function in elderly indi-
viduals.13 14 At a physician level, the cause of these negative 
health outcomes of polypharmacy may be inappropriate 
prescribing, including undertreatment.15–18 At a patient 
level, a high number of drugs and the complexity of a 
drug regimen is often associated with poor adherence,19 
which may be exacerbated by the presence of depression 
and/or cognitive impairment.20 Moreover, polypharmacy 
may also result in an accumulation of potentially inappro-
priate medications (PIMs).
Several complex interventions have been developed 
to optimise (inappropriate) polypharmacy. However, 
despite their evidence- based rationale, they have led to 
inconsistent improvements in process parameters of 
care and failed to impact patient- relevant outcomes.21 22 
One possible reason for this is that the included popu-
lations are too heterogeneous in terms of their baseline 
risk and potentially achievable intervention effects. For 
example, the majority of the study population included 
in the PRIMUM (PRIoritising MUltimedication in Multi-
morbidity) trial showed very good quality of life and func-
tional status at baseline, even though participants had at 
least three chronic conditions affecting more than two 
organ systems, five or more chronic drug prescriptions 
and were 60 years of age or older. The authors therefore 
concluded that there was not enough room for improve-
ment.23 This highlights current difficulties in defining 
inclusion criteria in polypharmacy trials in such a way that 
selected populations have a considerable baseline risk 
and can be expected to benefit from the intervention. 
Moreover, as polypharmacy interventions tend to address 
inappropriate prescribing, healthcare coordination, and 
so on, they are generally complex.21 22 As the complex 
interventions are also resource- intensive, it would be pref-
erable for a stratified approach to address patients that 
are at high risk of negative health outcomes and most 
likely to benefit from them.24
The course of multimorbidity (and associated poly-
pharmacy) has been characterised by a decline in well- 
being (eg, functional decline or worsening of quality of 
life due to inappropriate prescriptions and/or deterio-
ration in one or more chronic diseases), interrupted by 
adverse events (eg, exacerbations of chronic diseases or 
adverse drug reactions).25 26 In order to identify a popula-
tion at high risk, it is therefore necessary to predict a wide 
array of possible negative health outcomes. Several prog-
nostic models have predicted single outcomes, mainly 
mortality or unplanned hospital (re- )admission and to 
a lesser extent a future decline in quality of life, but no 
studies have investigated the risk for the above- mentioned 
combined endpoints, or involved polypharmacy- related 
predictors.27
The aim of this exploratory study was to develop and 
internally validate prognostic models to predict the risk 
of adverse events or a decline in well- being in general 
practice patients with multimorbidity and polypharmacy, 
and to operationalise these negative health outcomes in 
terms of hospitalisation, falls, level of required nursing 
care, institutionalisation and HRQoL. The models were 
based on morbidity and medication- related variables, as 
well as socio- demographic characteristics and parameters 
of healthcare utilisation.
METHODS
We developed and internally validated prognostic models 
to identify key health problems linked with multimor-
bidity and associated polypharmacy (decline in well- being 
and adverse events: figure 1). (1) Based on claims data, 
we predicted the combined endpoint of hospitalisation, 
falls/fall- related injuries, need for nursing care, deteri-
oration in the required level of care (nursing level) or 
institutionalisation, after 6, 9 and 24 months. (2) We 
predicted HRQoL after 6 and 9 months based on data 
from a cluster- randomised trial.23
Design and setting/study samples
Two data sets were used in modelling:
Claims data obtained from the Techniker Krankenkasse 
(TK) statutory health insurance company between 
January 2012 and December 2014. TK is the largest stat-
utory health insurer in Germany and provided health 
insurance to 8.1 million persons in 2012.28 In accor-
dance with Social Code book V, all statutory health 
insurance companies in Germany collect basic data on 
socio- demographics, details of pharmacological and non- 
pharmacological prescriptions and information on other 
health services utilisation and data on morbidity.
Trial data from the cluster- randomised PRIMUM trial23 
conducted in general practices in Hesse, Germany, from 
August 2010 to February 2012.
Population
Claims- based models: We aimed to use the same inclusion 
criteria for both data sets as far as possible. We therefore 
included health insurance claims data of older patients 
(≥60 years) with multimorbidity (at least three docu-
mented chronic diseases, from a list of 46 diagnoses and 
conditions, from 01 January 2012 to 31 December 2012)29 
and polypharmacy (at least five documented and concur-
rent prescriptions from 01 July 2012 to 31 December 
2012). Included patients had to have been continuously 
insured by TK from 01 January 2012 to 31 December 2014 
(except in case of death at any time after 31 December 
2012) and had to have contacted a primary care provider 
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at least once in 2012. Patients were excluded if they were 
diagnosed with dementia (International Classification of 
Diseases, 10th Edition (ICD-10): F00-03, F05.1, G30-31, 
R54) or under guardianship from 01 January 2012 to 31 
December 2012.
Trial data- based models: We included data from patients 
that participated in the cluster- randomised PRIMUM 
trial (n=502, intervention group: n=252, control group 
n=250).23 Patients with multimorbidity and polypharmacy 
were included in the study if they were at least 60 years 
old, had at least three chronic diseases from two or more 
chapters of ICD-10 and at least five prescriptions. Patients 
were excluded if they were cognitively impaired (defined 
as a score lower or equal to 26 on the Mini- Mental Status 
Exam30), had an alcohol or drug addiction or were not 
able to participate in telephone interviews, fill in ques-
tionnaires or express their own free will. Four out of the 
502 patients (0.79%) died during the 9- month follow- up 
period.
Outcomes
Models based on claims data: We predicted the combined 
endpoint of hospitalisation, falls/fall- related injuries or 
institutionalisation in a long- term care facility, or if the 
need for nursing care was recognised, or the level of 
care (‘Pflegestufe’) had worsened at 6- month, 9- month, 
24- month follow- up. We treated the parameters of health 
service use (hospitalisation, level of nursing care and 
institutionalisation) as surrogate parameters for a decline 
in functional status and well- being, as details of these are 
not included in German claims data. Outcomes were 
operationalised as follows:
 ► Hospitalisation: We included all- cause hospitalisa-
tions, as our data did not permit us to differentiate 
between unplanned and elective hospitalisations.
 ► Falls and fall- related injuries: We included all frac-
tures and injuries coded in ICD-10 chapters ‘S’ and 
‘T’. We excluded ICD codes for severe body injuries 
such as S31 (‘open wound of abdomen, lower back 
and pelvis’), which we assessed as related to severe 
bodily impact, rather than drug- related falls (see 
online supplemental additional file 1 for all excluded 
ICD codes). We also excluded osteoporosis- related 
fractures (ICD-10 M80).
 ► Institutionalisation was defined as the admission of a 
patient to a long- term care facility for at least 28 days 
(in Germany, this is the maximum length of time 
considered as ‘short- term care’ in such facilities).
 ► Level of (nursing) care (‘Pflegestufe’) referred to 
dependency on care. In the period under review, the 
German nursing care insurance system recognised 
four levels of care (‘1’ – lowest level to ‘3’ – highest 
level, and ‘H’, which was mainly used for people with 
mental illnesses who are in need for support). The 
onset of care and any increase in care level were taken 
into consideration.
Models based on trial data: We predicted HRQoL 6 and 
9 months after baseline. HRQoL was measured using the 
EQ- 5D- 3L index score.31–33 The EQ- 5D- 3L index score 
is a weighted summary score of five different dimen-
sions of health (mobility, self- care, usual activities, pain/
discomfort and anxiety/depression). Each dimension has 
three levels. The index score is calculated based on time 
Figure 1 Predicted outcomes with regard to general trajectories of well- being and quality of life over time. HRQoL, health- 
related quality of life.
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trade- off (TTO) norm values and ranges from 0 to 1, with 
‘0’ signifying death and ‘1’ in full health. Patients who 
died during follow- up were assigned the value ‘0’.
Potential predictors
The potential predictors that were initially used in the two 
modelling approaches were available in both claims and 
trial data (‘core predictors’, see figure 2): To compare the 
two models, we first used these ’core predictors’ (all vari-
ables were continuous variables, if not stated otherwise).
 ► Socio- demographics: Age (in years), sex (male/
female, binary)
 ► Morbidity- related (excluding dementia): Number 
of chronic diseases (based on a modified list of 46 
diagnoses and conditions),29 Charlson comorbidity 
index,34 number of specific chronic conditions 
according to Diederichs’ list35 consisting of 17 chronic 
diseases identified in a systematic review of existing 
comorbidity indices. As dementia was excluded, the 
final list contained 16 diagnoses. (All instruments 
including ICD-10 codes are provided in online supple-
mental additional file 2)
 ► Medication: Number of prescriptions (defined as 
Anatomical Therapeutic Chemical (ATC) agents 
using fifth- level coding, ATC version 2011 to 2014), 
excluding drugs for topical applications and drug 
groups that were irrelevant to our research question, 
for example, contrast agents (ATC V-08, three- digit 
level).
 ► Potentially inappropriate medication: We constructed 
two patient co- variables: (1) exposure to any PIM 
(yes/no) and (2) number of PIMs between 01 July 
2012 and 31 December 2012 (claims- based models) 
and at baseline (trial data- based models). We used the 
following two lists to identify PIMs:
 – Modified EU- PIM list36: The list of PIMs for the elder-
ly contains 282 chemical substances or drug classes 
divided into 34 therapeutic groups.
 – Modified PRISCUS list37: The German list of PIMs for 
the elderly includes 83 chemical substances from a 
total of 18 drug classes.
We excluded from the lists PIMs that referred to 
specific doses, treatment duration and disease se-
verity, as valid information on these could not be 
obtained from the claims data. (All instruments in-
cluding ATC codes are provided in online supple-
mental additional file 3)
 ► Anticholinergic drug burden: Scores were calculated 
based on all prescribed drugs with anticholinergic 
properties per patient. Despite substantial differences 
between existing scales, associations with adverse 
clinical outcomes, such as hospital admissions, fall- 
related hospitalisations, length of stays in hospital, 
and general practitioner (GP) visits, have been found 
for all of them.38 As the evidence does not support 
the preferred use of any particular scale, we tested the 
following (all instruments including ATC codes are 
provided in online supplemental additional file 3):
 – Anticholinergic Drug Scale (ADS)39 : The ADS weights 
anticholinergic properties per drug from ‘0’ – no 
anticholinergic activity, ‘1’ – mild, ‘2’ – moderate 
and ‘3’ – strong anticholinergic activity. The overall 
anticholinergic burden per patient was calculated 
as a sum score for the entire medication regimen.
 – Modified Anticholinergic Drug Burden Index (DBI)13 
: The DBI comprises drugs with sedative effects 
(which form the sedative burden (BS)), and drugs 
with anticholinergic or both sedative and anti-
cholinergic effects (which form the anticholiner-
gic burden (BAC)). As claims data do not provide 
Figure 2 Models and sensitivity analyses with regard to data source and predictor set. CRT, cluster- randomised controlled 
trial; †Best Model.
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dosages, the cumulative number of sedative and 
anticholinergic drugs was calculated (modified 
DBI score).
 ► Healthcare utilisation: For each patient, we obtained 
information on all- cause hospitalisations (yes/
no), falls and fall- related injuries (yes/no) and the 
number of physicians involved in ambulatory health-
care, between 01 January 2012 and 31 December 2012 
for models based on claims data, and in the 6 months 
previous to baseline for models based on trial data.
Additional potential predictor variables were used exclusively 
to re- fit models based on trial data, as they were only available in 
these data (‘additional predictors’, see figure 2; all variables 
were continuous variables unless stated otherwise):
1. Socio- demographics: Education (CASMIN40) and 
number of persons living in the household.
2. Lifestyle: Alcohol consumption (audit- C, categorical 
variables on number of drinking occasions and amount 
of alcohol consumed),41 smoking status (smoker/non- 
smoker, binary) and body mass index.
3. Inappropriateness of medication: MAI consists of 10 
items (indication, effectiveness, correctness of dos-
age, correctness of direction, practicality of direction, 
drug–drug interactions, drug–disease interactions, 
unnecessary drug duplications, correctness of treat-
ment duration and costs).42 The MAI item on cost was 
omitted because variable discount contracts between 
pharmaceutical companies and statutory health insur-
ers preclude cost comparisons in Germany. The med-
ication reviews were conducted by a trained clinical 
pharmacologist (SH), who rated nine items for each 
prescription. Values ranged from ‘0’ (appropriate) to 
‘2’ (inappropriate) whereby ‘1’ represented a middle 
rating of uncertain appropriateness. The assigned val-
ues were summed to give an MAI score between 0 and 
18 for each prescription and across the entire medica-
tion regimen of the patient.23
4. Morbidity- related: Severity of multimorbidity, as mea-
sured using the CIRS (the CIRS differentiates between 
14 organ systems, which are assessed on a 5- point 
Likert scale according to severity of impairment, with 
the ratings ranging from no impairment to extreme 
impairment),43 with scores calculated as the total sum 
score, the number of affected organ systems and the 
HRQoL- CI (HRQoL- CI consists of a mental and a 
physical subscale, whereby the presence of certain dis-
eases are assigned weights from ‘1’ to ‘3’, see online 
supplemental additional file 2).44
5. Depressive symptoms, as measured using the GDS with 
15 items.45
6. HRQoL at baseline, as measured using the EQ- 5D- 3L 
index score.31–33
Missing values and imputation
There were no missing values in the claims data, so no 
imputation was carried out in models that were based 
on them. In models based on trial data, imputation of 
missing values in predictors and outcomes was conducted 
using multiple imputation via chained equations.46 47 We 
used a fully conditional specification approach by setting 
up an appropriate conditional density for each variable. 
In the imputation process, we included all variables that 
were used in each model. We imputed m=50 data sets and 
combined the results using ‘Rubin’s rules’.46
Statistical analyses
In both models, we first investigated the core predictors 
that were available in both data sets, including socio- 
demographics, morbidity- related and medication- related 
variables and variables for healthcare utilisation. We then 
refitted the trial data- based models using the additional 
predictors that were exclusively available for trial data, 
such as variables for lifestyle and well- being (figure 2).
Models based on claims data: In order to develop a predic-
tion model for the binary combined outcome (containing 
all- cause hospitalisation, falls/fall- related injuries, insti-
tutionalisation or level of (nursing) care required) at 
6- month, 9- month and 24- month follow- up, we performed 
multiple logistic regression analyses with the occurrence 
of at least one of the components at 6- month, 9- month 
and 24- month follow- up as the dependent variable. As 
patients were not always assigned a single general prac-
tice,48 we did not perform cluster analysis on the claims 
data.
Models based on trial data: In order to develop a predic-
tion model for the continuous outcome HRQoL at 
6- month and 9- month follow- up, we performed multiple 
linear regression analyses using the EQ- 5D- 3L index 
score at 6- month and 9- month follow- up as the depen-
dent variable. The cluster structure of the data was taken 
into account by including a random intercept to produce 
a mixed regression model. We assumed a compound 
symmetry structure when estimating the covariance 
matrix.
Univariate analyses in both claims and trial data: Prior to 
conducting regression analyses, we performed univariate 
analyses to identify any associations between our potential 
predictors (at baseline) and the outcomes (at 6- month, 
9- month and 24- month follow- up).
Regression analyses and variable selection: To find out which 
predictor variables influence the outcome variables, we 
used a stepwise variable selection procedure (combining 
forward and backward steps). We started with the full 
model and all potential predictor variables. After this, we 
used a selection procedure based on p values.49 In the 
backward selection step, we deleted the variable with the 
highest p value from the model if its p value was greater 
than 0.157. In the forward selection step, the variable 
with the lowest p value was included in the model if its p 
value was less than 0.156. As long as each covariate had 
only one df, the use of these boundaries led to the same 
results as variable selection using the Akaike Informa-
tion Criterion.50 The resulting models are presented by 
providing the estimated regression coefficients (models 
based on trial data) or ORs (models based on claims) 
with 95% CIs and corresponding p values. As we expected 
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the large sample size of claims- based models to result in 
low p values, we calculated additional z values and contin-
uous net reclassification indices to gain information on 
the predictive power of each variable.51 Multi- collinearity 
was assessed using the variance inflation factor (VIF).52 In 
the models based on trial data, we did not account for the 
clustering structure when we calculated the VIF.
Performance of the models
We calculated R2 for linear models based on trial data 
(according to Nakagawa and Schielzeth53), and Nagelk-
erke’s R2 for logistic models (according to Steyerberg 
and Nagelkerke54 55) based on claims data. Furthermore, 
in order to assess performance more realistically and to 
internally validate the models, we used the AUC (area 
under the receiver operator curve, equivalent to the 
concordance index) to validate the logistic regression 
model based on claims data, and R2 to validate the linear 
regression model based on randomised controlled trial 
data, in combination with 10- fold cross- validation.56 R2 
and Nagelkerke’s R2 are measures of the overall model’s 
ability to assess explained variance. The AUC provides a 
measure of the model’s discriminatory ability to distin-
guish patients at risk from those that are not.
Sensitivity analyses
Using sensitivity analysis, we applied two further model-
ling approaches (at first separately and then in combina-
tion): (1) modelling without multiple imputation and (2) 
modelling without variable selection.
Software: We made use of different statistical packages to 
analyse the data in R.47 57–63
We used TRIPOD reporting guidelines (Transparent 
Reporting of a multivariable prediction model for Indi-
vidual Prognosis Or Diagnosis) in the preparation of this 
manuscript.64
Patient and public involvement statement
Neither patients nor the public were involved in this study.
RESULTS
Participants
Claims data
The total sample of those ≥60 years that were continu-
ously insured by TK from 01 January 2012 to 31 December 
2014, and had at least one primary care contact during 
2012, amounted to 1 377 917 persons. Overall, 592 456 
patients met the pre- specified criteria and were included 
in the analyses (see study flow- chart, online supplemental 
additional file 4).
Trial data
Of the 505 patients that participated in the PRIMUM 
trial, all but 3 were 60 years or older. The final analyses 
therefore included 502 patients.
Key characteristics of study participants are shown in 
table 1.
Univariate analyses
In the claims data, univariate analyses revealed significant 
associations between the combined outcome and the 
following predictors: Age, sex, disease count, Charlson 
Comorbidity Index, EU- PIMs, ADS, DBI, previous hospi-
talisations, previous falls and number of physicians 
involved in the patient’s care at all follow- ups (after 6, 9 
and 24 months) (online supplemental additional file 5). 
In the trial data, HRQoL was significantly correlated with 
the shared predictor variables disease count, number 
of chronic prescriptions, previous falls and sex and the 
additional predictors depression and HRQoL at baseline 
(online supplemental additional file 6).
Prognostic models
Claims data
The model predicting the combined endpoint at 6 months 
had the highest C- statistic (AUC with 10- fold cross valida-
tion: 0.71, see table 2), but a low explanation of variance 
(Nagelkerke’s R2 without cross validation: 0.16). Vari-
ables in the model with the highest predictive power were 
previous falls/fall- related injuries and previous hospital-
isations, as well as age, number of involved physicians, and 
number of chronic diseases (‘disease count’) (table 3). 
The models predicting the combined outcome at 9 and 
24 months had AUCs calculated with 10- fold cross valida-
tion of 0.68 (R² without cross validation: 0.15) and 0.69 
(R² without cross validation: 0.13) respectively. The VIF 
(to assess any multi- collinearity) showed moderate values 
(maximum 7.5).
Trial data
All results presented in this section are based on the 
modelling approach and involve multiple imputation 
of missing values and the variable selection procedure. 
Models predicting the HRQoL endpoint at 6 months that 
were based on core predictors available in both claims and 
trial data showed low predictive accuracy (R2 with 10- fold 
cross validation: 0.111) (table 3, model 2.4). HRQoL at 
6 months was best predicted when additional predictors 
that were exclusively available in the trial data were also 
included (R2 with 10- fold cross validation: 0.507). The 
variables with the highest predictive power were depres-
sive symptoms (GDS) and EQ- 5D- 3L Index Score (Base-
line). MAI was also predictive (table 3, model 3.4). The 
VIF showed small values (maximum 2.2).
Comparison of model quality and sensitivity analyses
The shorter the time span of the prediction, the better 
the explained variance and hence, the performance of 
the model. However, model performance remained fair 
to poor when it only included predictor variables that 
were available for both claims and trial data. Sensitivity 
analyses confirmed these results (table 2).
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Table 1 Characteristics of study participants
Characteristic
Claims data*
n=592 456
CRT data*
n=502
Data collection period January 2012 to December 2014† August 2010 to February 2012
Study design Cohort study Cluster- randomised controlled trial
Setting Claims data from the TK health insurance 
fund. TK serves about 10 million people 
in Germany
72 general practices in Hesse, Germany
Inclusion criteria ≥60 years ≥60 years
≥3 chronic diseases ≥3 chronic diseases
≥5 prescriptions ≥5 prescriptions
≥1 GP visit
Continuously insured (except in case of 
death in follow- up period)
≥1 GP visit
Exclusion criteria Person under legal guardianship
Diagnosed dementia
Person under legal guardianship
Cognitive dysfunction including dementia 
(MMSE ≤26)
Outcomes to be predicted Combined‡ binary outcome after 
6- month, 9- month, 24 month follow- up
HRQoL (continuous outcome) after 
6- month and 9- month follow- up
Potential predictors in both samples at baseline¶
Age (years) 71.3 (7.06) 72.2 (6.86)
Male sex (n, %) 319 453 (54) 240 (48)
Morbidity
  Disease count 9.7 (3.75) 9.6 (3.25)
  No. of specific chronic diseases 
(Diederichs)
4.3 (1.97) 4.1 (1.60)
  CCI 3.0 (2.54) 2.6 (1.92)
  HRQoL- CI, mental 2.8 (2.12) 2.1 (1.81)
  HRQoL- CI, physical 8.0 (3.57) 7.6 (3.12)
Medication
  No. of drugs 8.6 (3.80) 8.1 (2.57)
  No. of PIM (EU- PIM) 1.1 (1.15) 0.9 (0.96)
  ACh burden (ADS) 1.0 (1.45) 0.8 (1.21)
  Modified Drug Burden Index 0.8 (1.03) 0.5 (0.77)
No. of involved physicians 9.95 (5.26) 2.6 (1.77)
Previous hospitalisation:
  Patients that have undergone hospital 
treatment (n, %)
194 984 (33) 81 (16)§
  No. of hospitalisations 1.67 (1.25) 1.5 (0.86)§
  No. of days in hospital 14.5 (18.20) 17 (12.66)§
Patients with previous falls/fall- related 
injuries (n, %)
163 387 (28) 83 (17)§
Patients requiring nursing care
  Any nursing level (n, %) 28 310 (5) –
  Nursing level 1 (n, %) 19 030 (3) –
  Nursing level 2 (n, %) 7968 (1) –
  Nursing level 3 (n, %) 1273 (0.2) –
  Nursing level H (n, %) 39 (0.007) –
Additional predictor variables in CRT data at baseline¶
Socio- demographics
Continued
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DISCUSSION
Main results
Our best overall prognostic model predicted HRQoL 
after 6 months in older general practice patients with 
multimorbidity and polypharmacy. It performed well, 
was based on trial data and explained more than half 
of the variance. The most important predictors were 
depressive symptoms, the initial level of HRQoL and 
MAI—all of which were only available as ‘additional 
predictors’ in trial data. Prognostic models in trial data, 
which were exclusively developed from ‘core predictors’ 
(available in both data sets) performed worse, as well as 
claims based models and models based on both data sets 
that had longer forecast periods (9 months or more). In 
both trial data- based and claims- based models, outcome 
components at baseline had a relatively high impact (ie, 
HRQoL at baseline in the trial data- based model and 
previous hospitalisation and previous falls/fall- related 
injuries in claims- based models). Although this is unsur-
prising and is often the case in prognostic models,65 it 
nonetheless seems reasonable to retain the variables in 
the model. Furthermore, we identified further predic-
tors, such as depressive symptoms and medication 
appropriateness, which had a relatively high predictive 
power.
Comparison with the literature
The presented results are consistent with results from 
other studies. The AUC values in our claims- based models 
(AUC 0.68 to 0.71) are comparable to those of 23 prog-
nostic models for Case Finding conducted in elderly 
patients in primary care. These models predicted (re)
hospitalisation, functional impairment, institutionalisa-
tion and death.65 The quality of models with a low risk of 
bias was AUC 0.60 to 0.78, but no explanation of variance 
was provided. The best model for predicting death within 
4 years (AUC: 0.82) included 12 predictors comprising 
age, sex, body mass index, chronic diseases, smoking status 
and functional parameters.65 Models that included addi-
tional trial data (eg, clinical data) predicted endpoints 
better than models based only on claims data.65–67 In many 
models described in other studies, healthcare utilisation 
parameters, and especially previous hospitalisations, were 
predictive of (re)hospitalisations, emergency admissions 
and functional impairment.66 68 69 The predictive power of 
sex is inconsistent: in 18/27 risk models, sex was included 
in the final model;66 in 7/23 risk models, male sex was 
predictive,65 while a further 25 studies found sex to have 
no influence.68 69 Model quality also improved in studies 
that included multimorbidity and polypharmacy parame-
ters.66 68 70 However, the parameters and instruments used 
Characteristic
Claims data*
n=592 456
CRT data*
n=502
  Educational level (CASMIN) – 1.4 (0.66)
  No. of persons living in household – 1.8 (0.70)
Lifestyle
  Alcohol intake (AUDIT C) – 1.9 (1.96) (mv: 39)
  Smoker (n, %) – 46 (10) (mv: 25)
  Body mass index – 30.1 (6.58)
Morbidity
  CIRS sum score 7.7 (4.56)
  CIRS, no. of organ systems 4.5 (2.35)
  Depressive Symptoms (GDS) 2.4 (2.29) (mv: 8)
Medication
  MAI – 4.7 (5.56)
HRQoL
  EQ- 5D- 3L Index Score – 74.3 (23.72) (mv: 24)
*Values are arithmetic means and SD unless otherwise indicated.
†The anamnestic period for baseline data ran from 01 January 2012 to 31 December 2012, except for medication data, for which it ran from 
01 July 2012 to 31 December 2012. The follow- up period started on 01 January 2013.
‡Combined outcome included hospitalisation, fall/fall- related injuries, institutionalisation and care level.
§6 months before study entry.
¶Number of patients with missing values (mv) is zero unless indicated in square parentheses.
ACh burden, anticholinergic drug burden; ADS, Anticholinergic Drug Scale; AUDIT, Alcohol Use Disorders Identification Test (WHO); CASMIN, 
Comparative Analysis of Social Mobility in Industrial Nations; CCI, Charlson Comorbidity Index; CIRS, Cumulative Illness Rating Scale; CRT, 
cluster- randomised controlled trial; GDS, Geriatric Depression Scale; GP, general practitioner; HRQoL, health- related quality of life; HRQoL- 
CI, HRQoL comorbidity index; MAI, Medication Appropriateness Index; MMSE, Mini- Mental Status Exam; PIM, potentially inappropriate 
medication; TK, Techniker Krankenkasse.
Table 1 Continued
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in modelling (eg, CIRS, Charlson Comorbidity Index 
and disease count, as reported here) varied considerably 
among studies. They were neither consistently predictive, 
nor were certain parameters or instruments better than 
others.66 69 70
Most published models were developed to predict the 
risk of hospitalisation.66 68–74 Other models predicted 
functional outcomes,70 while four models predicted 
adverse drug reactions.74 So far, little is known about the 
predictive power of polypharmacy parameters and the 
appropriateness of prescriptions, especially the MAI has 
never been used in prognostic models. Furthermore, 
no models have yet been developed to predict HRQoL 
in patients with multimorbidity and polypharmacy in 
general practice.27 70
Strengths and limitations
One strength of our study is that we could use two data 
sources with differing advantages in our exploratory anal-
ysis: claims data contained a large number of cases, and 
Table 2 Comparison of models
Models based on claims data: core predictors AUC* R2
1.1 Combined outcome after 6 months 0.71 (0.70) 0.16 (0.16)
1.2 Combined outcome after 9 months 0.69 (0.69) 0.15 (0.14)
1.3 Combined outcome after 24 months 0.68 (0.68) 0.13 (0.12)
Models based on CRT data: core predictors* AIC R2 R2 (10x)
EQ- 5D- 3L after 6 months
2.1 No imputation, no variable selection 4138.86 (4069.41) 0.155 (0.159) 0.112 (0.103)
2.2 No imputation, with variable selection 4138.81 (4068.69) 0.150 (0.155) 0.129 (0.122)
2.3 With imputation, no variable selection 4582.30 (4507.71) 0.159 (0.163) 0.094 (0.108)
2.4 With imputation, with variable selection 4583.15 (4507.47) 0.919 (0.925) 0.111 (0.128)
EQ- 5D- 3L after 9 months
2.5 No imputation, no variable selection 3917.75 (3917.75) 0.150 (0.150) 0.030 (0.030)
2.6 No imputation, with variable selection 3921.95 (3921.95) 0.146 (0.146) 0.053 (0.053)
2.7 With imputation, no variable selection 4540.58 (4505.52) 0.156 (0.152) 0.090 (0.093)
2.8 With imputation, with variable selection 4546.42 (4511.10) 0.221 (0.218) 0.107 (0.106)
Models based on CRT data: core predictors and 
additional predictors*
EQ- 5D, after 6 months
3.1 No imputation, no variable selection 3205.13 (3205.13) 0.034 (0.034) 0.442 (0.442)
3.2 With imputation, no variable selection 4308.94 (4308.94) 0.538 (0.538) 0.481 (0.481)
3.3 No imputation, with variable selection 3197.37 (3197.37) 0.526 (0.526) 0.483 (0.483)
3.4 With imputation, with variable selection† 4307.47 (4307.47) 0.677 (0.677) 0.507 (0.507)
Models with ‘fixed variables’
3.5 No imputation, no variable selection 3208.58 (3208.58) 0.514 (0.514) 0.468 (0.468)
3.6 With imputation, with variable selection 4308.90 (4308.90) 0.665 (0.665) 0.499 (0.499)
EQ- 5D, after 9 months
3.7 No imputation, no variable selection 3061.06 (3113.53) 0.042 (0.028) 0.411 (0.409)
3.8 With imputation, no variable selection 4307.28 (4361.36) 0.498 (0.477) 0.433 (0.404)
3.9 No imputation, with variable selection 3062.03 (3108.61) 0.490 (0.485) 0.448 (0.443)
3.10 With imputation, with variable selection 4309.88 (4360.32) 0.453 (0.346) 0.455 (0.431)
Models with fixed variables
3.11 No imputation, no variable selection 3064.76 (3113.08) 0.490 (0.485) 0.439 (0.434)
3.12 With imputation, with variable selection 4310.92 (4363.62) 0.113 (0.071) 0.447 (0.423)
(sensitivity analyses)
*Models based on randomised controlled trial data: fixed effects.
†Best overall model.
AIC, Akaike Information Criterion; AUC, area under the curve after 10- fold cross validation; R², Nagelkerke’s R²; R2 (10x), Nagelkerke’s R² with 
10- fold cross validation.
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trial data provided additional high- quality patient data 
including functional status and HRQoL. Both data sets 
also have their limitations, since claims are documented 
for billing purposes and are therefore imprecise, whereas 
our trial data set consisted of only a limited number of 
observations. Thus, each data set allows its own endpoints 
to be modelled. Risk modelling is especially complex in 
multimorbid patients with polypharmacy, as predictor 
variables in this patient collective are often associated 
with one another (eg, diagnoses and prescriptions). 
In addition, comparable risk situations can lead to 
different endpoints, as risk often depends on context. 
For example, a drug- induced fall may have no health- 
related consequences or may lead to impairment and 
institutionalisation.
Further to these key limitations, our results need 
careful interpretation for several reasons: First, the 
combined endpoint in the claims- based models yielded 
a high event rate, which may have resulted in overopti-
mistic results in our logistic regression. However, other 
approaches would not have resolved this problem to suit 
our purposes either. Additionally, we still have enough 
cases in both categories of the dependent variable to 
conduct a valid model estimation. Nonetheless, the low 
performance of the claims model may have been because 
predictors acted in different ways on the different 
elements of the combined outcome, thus resulting in 
greater heterogeneity.75 Second, the small sample size 
of the trial population may have led to some overfitting 
of the model. At the same time, the VIF (to assess any 
Table 3 Best performing models per data set and set of predictors
Best model based on claims data: core 
predictors (model 1.1) OR (95% CI) P value z- value NRI
Age (years) 1.02 (1.02 to 1.02) <0.001 45.4 0.11
Sex (female) 0.99 (0.97 to 1.00) 0.025 −2.2 −0.03
Disease count 1.02 (1.02 to 1.03) <0.001 19.2 0.05
CCI 1.03 (1.03 to 1.04) <0.001 22.7 0.02
No. of specific chronic diseases (Diederichs) 1.01 (1.00 to 1.01) <0.001 3.9 0.01
No. of PIM (EU- PIM) 1.03 (1.02 to 1.03) <0.001 8.9 0.02
ACh burden (ADS) 1.04 (1.03 to 1.05) <0.001 14.9 0.04
Modified Drug Burden Index 1.08 (1.07 to 1.08) <0.001 20.1 0.08
Previous hospitalisations 1.67 (1.65 to 1.70) <0.001 82.3 0.34
Previous falls/fall- related injuries 3.29 (3.25 to 3.34) <0.001 188.6 0.55
No. of involved physicians 1.02 (1.02 to 1.02) <0.001 29.0 0.08
Best model based on CRT data: core predictors 
(model 2.4)
Coefficient (95% CI) P value
Intercept 101.18 (93.11 to 109.25) <0.001
Sex (female) −11.26 (−15.59 to −6.94) <0.001
No. of specific chronic diseases (Diederichs) −2.18 (−3.64 to −0.73) 0.004
No. of drugs −1.28 (−2.23 to −0.32) 0.010
Modified Drug Burden Index −5.19 (−8.26 to −2.12) 0.001
Previous falls −6.11 (−12.07 to −0.15) 0.045
Best model based on CRT data: core predictors 
and additional predictors (model 3.4, best overall 
model)
Coefficient (95% CI) P value
Intercept 51.74 (38.91 to 64.57) <0.001
Sex (female) −3.61 (−6.96 to −0.27) 0.036
No. of specific chronic diseases (Diederichs) −1.03 (−2.08 to 0.01) 0.055
No. of involved physicians 0.80 (−0.13 to 1.74) 0.093
Body mass index −0.28 (−0.53 to −0.03) 0.031
Medication Appropriateness Index −0.39 (−0.70 to −0.08) 0.015
Depressive symptoms (GDS) −2.73 (−3.56 to −1.91) <0.001
EQ- 5D Index Score (baseline) 0.55 (0.47 to 0.64) <0.001
ACh burden, anticholinergic drug burden; ADS, Anticholinergic Drug Scale; CCI, Charlson Comorbidity Index; GDS, Geriatric Depression 
Scale; NRI, continuous net reclassification index; PIM, potentially inappropriate medication.
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multi- collinearity) showed only up to moderate values. 
The application of shrinkage methods would have 
been a possible alternative to address this limitation.76 
However, there is an ongoing debate whether it solves 
such problems, and a recent study has suggested that 
although shrinkage can result in improved calibration, 
it may not be superior in terms of reducing overfitting.77 
Furthermore, shrinkage models lead to biassed estimates 
of the regression coefficients, thus making results more 
difficult to interpret. Third, in our modelling approach 
we tested disease- based indicators such as the Charlson 
Comorbidity Index and CIRS that were developed and 
validated for other purposes. However, we chose indica-
tors that showed a strong association with negative health 
outcomes.35
Relevance for primary care and research implications
As the models derived in our study have not been exter-
nally validated and our methods have some limitations, 
we do not claim to have developed comprehensive prog-
nostic models to identify older general practice patients 
with multimorbidity and polypharmacy at risk of negative 
health outcomes. For this reason, we plan to conduct 
an individual patient data- based meta- analysis to further 
develop and externally validate the models presented 
here (PROSPERO ID: CRD42018088129).
It is, however, very likely that baseline components of 
our predicted endpoints are important predictors, espe-
cially considering these results are unsurprising and 
entirely plausible. A decline in HRQoL, a previous hospi-
talisation and a previous falls/fall- related injury can there-
fore be seen as a warning parameter ('red flag') that may 
help general practitioners in recognising older patients 
with multimorbidity and polypharmacy at high risk of 
adverse health outcomes. These patients are therefore 
more likely to benefit from an intervention than others 
with low or no risk.24 Hence, researchers evaluating poly-
pharmacy interventions, such as medication reviews, may 
like to consider our models when deciding on selection 
and inclusion criteria for a study population.
CONCLUSIONS
This study provides prognostic models to identify older 
general practice patients with multimorbidity and poly-
pharmacy at high risk of deterioration in HRQoL, hospi-
talisation, falls/fall- related injuries, institutionalisation 
and a need of nursing care. Outcome components, such 
as previous falls, hospital stays, reduced HRQoL and 
depression, were important predictors of these negative 
health outcomes in our models. They can be seen as 
warning signs of future worsening and an indication that 
these patients are likely to benefit from interventions to 
optimise their medication. Future studies should exter-
nally validate the models and evaluate the effectiveness of 
polypharmacy interventions in high- risk patients.
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Additional file 1: Falls and fall-related injuries: list of excluded ICD-10-codes  
Conditions ICD-10-Code  
(ICD-10-GM Version 2014) 
 Osteoporosis with pathological fracture M80 
 Open wound of neck S11 
 Dislocation, sprain and strain of joints and 
ligaments at neck level 
S13 
 Injury of nerves and spinal cord at neck level S14 
 Injury of blood vessels at neck level S15 
 Injury of muscle and tendon at neck level S16 
 Crushing injury of neck S17 
 Traumatic amputation at neck level S18 
 Other and unspecified injuries of neck S19 
 Injury of blood vessels of thorax S25 
 Injury of heart S26 
 Injury of other and unspecified intrathoracic 
organs 
S27 
 Crushing injury of thorax and traumatic amputation 
of part of thorax 
S28 
 Other and unspecified injuries of thorax S29 
 Open wound of abdomen, lower back and pelvis S31 
 Injury of blood vessels at abdomen, lower back 
and pelvis level 
S35 
 Injury of pancreas S36.2 
 Injury of stomach S36.3 
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 Injury of small intestine S36.4 
 Injury of colon S36.5 
 Injury of rectum S36.6 
 Injury of multiple intra-abdominal organs S36.7 
 Injury of other intra-abdominal organs  S36.8 
 Injury of ureter S37.1 
 Injury of bladder S37.2 
 Injury of urethra S37.3 
 Injury of ovary S37.4 
 Injury of fallopian tube S37.5 
 Injury of uterus S37.6 
 Injury of multiple pelvic organs S37.7 
 Injury of other pelvic organs  S37.8 
 Crushing injury and traumatic amputation of part 
of abdomen, lower back and pelvis 
S38 
 Injury of intra-abdominal organ(s) with pelvic 
organ(s) 
S39.6 
 Other multiple injuries of abdomen, lower back 
and pelvis 
S39.7 
 Other specified injuries of abdomen, lower back 
and pelvis 
S39.8 
 Crushing injury of shoulder and upper arm S47 
 Traumatic amputation of shoulder and upper arm S48 
 Traumatic amputation of forearm S58 
 Traumatic amputation of wrist and hand S68 
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 Traumatic amputation of hip and thigh S78 
 Traumatic amputation of lower leg S88 
 Traumatic amputation of ankle and foot S98 
 Crushing injuries involving multiple body regions T04 
 Traumatic amputations involving multiple body 
regions 
T05 
 Effects of foreign body entering through natural 
orifice 
T15-19 
 Burns and corrosions T20-32 
 Frostbite T33-35 
 Poisoning by specified narcotics and 
psychodysleptic agents (hallucinogenic drugs) 
T40.0-T40.1, T40.3, T40.5-
T40.9 
 Toxic effects of substances chiefly nonmedicinal 
as to source 
T51-65 
 Other and unspecified effects of external causes T66-77 
 Complications of surgical and medical care, not 
elsewhere classified 
T80-87 
 Sequelae of injuries, of poisoning and of other 
consequences of external causes 
T90-98 
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Potentially inappropriate drugs EU-PIM ATC-Code 
2014
ATC-Code 2013 ATC-Code 2012 ATC-Code 
2011
Magnesium hydroxide 1 A02AA04 A02AA04 A02AA04 A02AA04
Aluminium-containing antacids 1 A02AB01 A02AB01 A02AB01 A02AB01
Aluminium-containing antacids 2 A02AB02 A02AB02 A02AB02 A02AB02
Aluminium-containing antacids 3 A02AB03 A02AB03 A02AB03 A02AB03
Aluminium-containing antacids 4 A02AB04 A02AB04 A02AB04 A02AB04
Aluminium-containing antacids 5 A02AB05 A02AB05 A02AB05 A02AB05
Aluminium-containing antacids 6 A02AB06 A02AB06 A02AB06 A02AB06
Aluminium-containing antacids 7 A02AB07 A02AB07 A02AB07 A02AB07
Aluminium-containing antacids 8 A02AB10 A02AB10 A02AB10 A02AB10
Aluminium-containing antacids 15 A02AD02 A02AD02 A02AD02 A02AD02
Aluminium-containing antacids 16 A02AD03 A02AD03 A02AD03 A02AD03
Aluminium-containing antacids 17 A02AD04 A02AD04 A02AD04 A02AD04
Aluminium-containing antacids 18 A02AD05 A02AD05 A02AD05 A02AD05
Aluminium-containing antacids 9 A02AD06 A02AD06 A02AD06 A02AD06
Aluminium-containing antacids 10 (Magnesium 
hydroxide 2)
A02AD10 A02AD10 A02AD10 A02AD10
Aluminium-containing antacids 11 A02AF01 A02AF01 A02AF01 A02AF01
Aluminium-containing antacids 12 A02AF03 A02AF03 A02AF03 A02AF03
Aluminium-containing antacids 13 A02AF04 A02AF04 A02AF04 A02AF04
Aluminium-containing antacids 14 A02AF05 A02AF05 A02AF05 A02AF05
Cimetidine 1 A02BA01 A02BA01 A02BA01 A02BA01
Ranitidine 1 A02BA02 A02BA02 A02BA02 A02BA02
Famotidine 1 A02BA03 A02BA03 A02BA03 A02BA03
Ranitidine 2 A02BA07 A02BA07 A02BA07 A02BA07 
Cimetidine 2 A02BA51 A02BA51 A02BA51 A02BA51
Famotidine 2 A02BA53 A02BA53 A02BA53 A02BA53
Mebeverine A03AA04 A03AA04 A03AA04 A03AA04
Trimebutine A03AA05 A03AA05 A03AA05 A03AA05
Dihexyverine A03AA08 A03AA08 A03AA08 A03AA08
Otilonium bromide 1 A03AB06 A03AB06 A03AB06 A03AB06
Tiemonium (iodide) 1 A03AB17 A03AB17 A03AB17 A03AB17 
Trospium 2 A03AB20 A03AB20 A03AB20 A03AB20
Pinaverium A03AX04 A03AX04 A03AX04 A03AX04
Belladonna alkaloids 2 A03BA01 A03BA01 A03BA01 A03BA01
Belladonna alkaloids 3 (Hyoscyamine 1) A03BA03 A03BA03 A03BA03 A03BA03
Belladonna alkaloids 4 A03BA04 A03BA04 A03BA04 A03BA04
Belladonna alkaloids 5 A03BA20 A03BA20 A03BA20 A03BA20
Belladonna alkaloids 6 A03BB01 A03BB01 A03BB01 A03BB01
Belladonna alkaloids 7 A03BB02 A03BB02 A03BB02 A03BB02
Belladonna alkaloids 8 A03BB03 A03BB03 A03BB03 A03BB03
Belladonna alkaloids 9 A03BB04 A03BB04 A03BB04 A03BB04
Belladonna alkaloids 10 A03BB05 A03BB05 A03BB05 A03BB05
Clidinium A03CA02 A03CA02 A03CA02 A03CA02
Otilonium bromide 2 A03CA04 A03CA04 A03CA04 A03CA04
Belladonna alkaloids 11 A03CB01 A03CB01 A03CB01 A03CB01
Belladonna alkaloids 12 A03CB02 A03CB02 A03CB02 A03CB02
Belladonna alkaloids 13 A03CB03 A03CB03 A03CB03 A03CB03
Belladonna alkaloids 14 A03CB04 A03CB04 A03CB04 A03CB04
Belladonna alkaloids 15 + Hyoscyamine 2 A03CB31 A03CB31 A03CB31 A03CB31
Belladonna alkaloids 16 A03CB37 A03CB37 A03CB37 A03CB37
Belladonna alkaloids 17 A03CB38 A03CB38 A03CB38 A03CB38
Pitofenone  A03DA02 A03DA02 A03DA02 A03DA02
Trospium 3 A03DA06 A03DA06 A03DA06 A03DA06
Tiemonium (iodide) 2 A03DA07 A03DA07 A03DA07 A03DA07
Belladonna alkaloids 18 A03DB04 A03DB04 A03DB04 A03DB04
Trospium 4 A03EA04 A03EA04 A03EA04 A03EA04
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open
 doi: 10.1136/bmjopen-2020-039747:e039747. 10 2020;BMJ Open, et al. Müller BS
Metoclopramide 1 A03FA01 A03FA01 A03FA01 A03FA01
Alizapride A03FA05 A03FA05 A03FA05 A03FA05
Metoclopramide 2 A03FA51 A03FA51 A03FA51 A03FA51
Dimenhydrinate 1 A04AB02 A04AB02 A04AB02 A04AB02
Meclozine 3 A04AB04 A04AB04 A04AB04 A04AB04
Diphenhydramine 3 A04AB05 A04AB05 A04AB05 A04AB05
Dimenhydrinate 2 A04AB52 A04AB52 A04AB52 A04AB52
Meclozine 4 A04AB54 A04AB54 A04AB54 A04AB54
Diphenhydramine 6 A04AB55 A04AB55 A04AB55 A04AB55
Doxylamine 4 A04AB56 A04AB56 A04AB56 A04AB56
Promethazine 3 A04AB58 A04AB58 A04AB58 A04AB58
Scopolamine 1 (=Hyoscin) A04AD01 A04AD01 A04AD01 A04AD01
Metopimazine A04AD05 A04AD05 A04AD05 A04AD05 
Scopolamine 2 (=Hyoscin) A04AD51 A04AD51 A04AD51 A04AD51
Viscous paraffin (=Liquid paraffin) 1 A06AA01 A06AA01 A06AA01 A06AA01
Docusate sodium (oral) A06AA02 A06AA02 A06AA02 A06AA02
Viscous paraffin (=Liquid paraffin) 2 A06AA51 A06AA51 A06AA51 A06AA51
Castor oil (=Ricinus communis, =Neoloid)  A06AB05 A06AB05 A06AB05 A06AB05
Senna glycosides 1 A06AB06 A06AB06 A06AB06 A06AB06
Cascara sagrada 1 A06AB07 A06AB07 A06AB07 A06AB07
Sodium picosulfate 1 A06AB08 A06AB08 A06AB08 A06AB08
Aloe 1 A06AB13 A06AB13 A06AB13 A06AB13
Belladonna alkaloids 1 A06AB30 A06AB30 A06AB30 A06AB30
Senna glycosides 2 A06AB56 A06AB56 A06AB56 A06AB56
Cascara sagrada 2 A06AB57 A06AB57 A06AB57 A06AB57
Sodium picosulfate 2 A06AB58 A06AB58 A06AB58 A06AB58
Aloe 2 A06AB63 A06AB63 A06AB63 A06AB63
Prucalopride A06AX05 A03AE04 A03AE04 A03AE04
Diphenoxylate-Atropin A07DA01 A07DA01 A07DA01 A07DA01
Racecadotril A07XA04 A07XA04 A07XA04 A07XA04
Norephedrine (=Phenylpropanolamine) 3 A08AA13 A08AA13 A08AA13 A08AA13
Norephedrine (=Phenylpropanolamine) 4 A08AA63 A08AA63 A08AA63 A08AA63
Glibenclamide 1 A10BB01 A10BB01 A10BB01 A10BB01
Chlorpropamide A10BB02 A10BB02 A10BB02 A10BB02
Carbutamide A10BB06 A10BB06 A10BB06 A10BB06
Glipizide A10BB07 A10BB07 A10BB07 A10BB07
Glimepiride 1 A10BB12 A10BB12 A10BB12 A10BB12
Glimepiride 2 A10BD04 A10BD04 A10BD04 A10BD04
Pioglitazone 3 A10BD05 A10BD05 A10BD05 A10BD05 
Glimepiride 3 + Pioglitazone 2 A10BD06 A10BD06 A10BD06 A10BD06
Sitagliptine 3 A10BD07 A10BD07 A10BD07 A10BD07
Vildagliptine 2 A10BD08 A10BD08 A10BD08 A10BD08
Pioglitazone 4 A10BD09 A10BD09 A10BD09 A10BD09
Pioglitazone 5 A10BD12 A10BD12 A10BD12 n/a
Sitagliptine 4 A10BD12 A10BD12 A10BD12 n/a
Glibenclamide 2 A10BD15 n/a n/a n/a
Acarbose A10BF01 A10BF01 A10BF01 A10BF01
Pioglitazone 1 A10BG03 A10BG03 A10BG03 A10BG03
Sitagliptine 1 A10BH01 A10BH01 A10BH01 A10BH01
Vildagliptine 1 A10BH02 A10BH02 A10BH02 A10BH02
Sitagliptine 2 A10BH51 n/a n/a n/a
Cyproheptadine 2 A15AA01 A15AA01 A15AA01 A15AA01
Cyproheptadine 3 A15AA51 A15AA51 A15AA51 A15AA51
Acenocoumarol B01AA07 B01AA07 B01AA07 B01AA07
Ticlopidine B01AC05 B01AC05 B01AC05 B01AC05
Dipyridamole 1 B01AC07 B01AC07 B01AC07 B01AC07
Prasugrel B01AC22 B01AC22 B01AC22 B01AC22
Dipyridamole 2 B01AC36 n/a n/a n/a
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Dabigatran B01AE07 B01AE07 B01AE07 B01AE07
Rivaroxaban B01AF01 B01AF01 B01AX06 B01AX06
Apixaban B01AF02 B01AF02 B01AX08 n/a
Acetyldigitoxin C01AA01 C01AA01 C01AA01 C01AA01
Acetyldigoxin 1 C01AA02 C01AA02 C01AA02 C01AA02
Digitoxin 1 C01AA04 C01AA04 C01AA04 C01AA04
Digoxin 1 C01AA05 C01AA05 C01AA05 C01AA05
Metildigoxin 1 C01AA08 C01AA08 C01AA08 C01AA08
Acetyldigoxin 2 C01AA52 C01AA52 C01AA52 C01AA52
Digitoxin 2 C01AA54 C01AA54 C01AA54 C01AA54 
Digoxin 2 C01AA55 C01AA55 C01AA55 C01AA55
Metildigoxin 2 C01AA58 C01AA58 C01AA58 C01AA58
Quinidine and combinations 1 C01BA01 C01BA01 C01BA01 C01BA01
Procainamide C01BA02 C01BA02 C01BA02 C01BA02
Disopyramide C01BA03  C01BA03  C01BA03  C01BA03  
Quinidine and combinations 2 C01BA51 C01BA51 C01BA51 C01BA51
Quinidine and combinations 3 C01BA71 C01BA71 C01BA71 C01BA71
Propafenone C01BC03 C01BC03 C01BC03 C01BC03
Flecainide C01BC04 C01BC04 C01BC04 C01BC04 
Amiodarone C01BD01 C01BD01 C01BD01 C01BD01
Dronedarone C01BD07 C01BD07 C01BD07 C01BD07
Dipyridamole 4 C01DX21 C01DX21 C01DX21 C01DX21
Dipyridamole 3 C01DX71 C01DX71 C01DX71 C01DX71
Indometacin 2 C01EB03 C01EB03 C01EB03 C01EB03
Trimetazidine C01EB15 C01EB15 C01EB15 C01EB15
Ivabradine C01EB17 C01EB17 C01EB17 C01EB17
Theophylline 2 C01EB22 C01EB22 C01EB22 C01EB22
Theophylline 3 C01EX66 C01EX66 C01EX66 C01EX66
Reserpine 1 C02AA02 C02AA02 C02AA02 C02AA02
Reserpine 2 C02AA52 C02AA52 C02AA52 C02AA52
Methyldopa 1 C02AB01 C02AB01 C02AB01 C02AB01
Methyldopa 2 C02AB02 C02AB02 C02AB02 C02AB02
Clonidine 1 C02AC01 C02AC01 C02AC01 C02AC01
Guanfacine C02AC02 C02AC02 C02AC02 C02AC02
Moxonidine 1 C02AC05 C02AC05 C02AC05 C02AC05
Rilmenidine C02AC06 C02AC06 C02AC06 C02AC06
Prazosin 1 C02CA01 C02CA01 C02CA01 C02CA01
Doxazosin 1 C02CA04 C02CA04 C02CA04 C02CA04
Urapidil C02CA06 C02CA06 C02CA06 C02CA06
Terazosin 2 C02CA08 C02CA08 C02CA08 C02CA08
Guanethidine 1 C02CC02 C02CC02 C02CC02 C02CC02
Hydralazine 1 C02DB02 C02DB02 C02DB02 C02DB02
Reserpine 3 C02LA01 C02LA01 C02LA01 C02LA01
Reserpine 4 C02LA51 C02LA51 C02LA51 C02LA51
Reserpine 5 C02LA71 C02LA71 C02LA71 C02LA71
Methyldopa 3 C02LB01 C02LB01 C02LB01 C02LB01
Clonidine 2 C02LC01 C02LC01 C02LC01 C02LC01
Moxonidine 2 C02LC05 C02LC05 C02LC05 C02LC05
Clonidine 3 C02LC51 C02LC51 C02LC51 C02LC51
Prazosin 2 C02LE01 C02LE01 C02LE01 C02LE01
Guanethidine 2 C02LF01 C02LF01 C02LF01 C02LF01
Hydralazine 2 C02LG02 C02LG02 C02LG02 C02LG02
Niacin (=Nicotinic acid) 2 C04AC51 C04AC51 C04AC51 C04AC51
Pentoxifylline C04AD03 C04AD03 C04AD03 C04AD03
Ergoloid mesylate (= dihydroergotoxine) 1 C04AE01 C04AE01 C04AE01 C04AE01
Nicergoline 1 C04AE02 C04AE02 C04AE02 C04AE02
Dihydroergocristine 1 C04AE04 C04AE04 C04AE04 C04AE04
Ergoloid mesylate (= dihydroergotoxine) 2 C04AE51 C04AE51 C04AE51 C04AE51
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Dihydroergocristine 2 C04AE54 C04AE54 C04AE54 C04AE54
Cyclandelate (=Cyclospasmol) 1 C04AX01 C04AX01 C04AX01 C04AX01
Vincamine 1 C04AX07 C04AX07 C04AX07 C04AX07
Moxisylyte 1 C04AX10 C04AX10 C04AX10 C04AX10
Piribedil 2 C04AX13 C04AX13 C04AX13 C04AX13
Vinburnine C04AX17 C04AX17 C04AX17 C04AX17
Buflomedil C04AX20 C04AX20 C04AX20 C04AX20
Naftidrofuryl C04AX21 C04AX21 C04AX21 C04AX21
Quinine and derivatives 5 C05AF01 C05AF01 C05AF01 C05AF01
Quinine and derivatives 6 C05AF51 C05AF51 C05AF51 C05AF51
Digitoxin 3 C05BZ05 C05BZ05 C05BZ05 C05BZ05
Escin (=Aescin) 3 C05BZ09 C05BZ09 C05BZ09 C05BZ09
Escin (=Aescin) 4 C05BZ59 C05BZ59 C05BZ59 C05BZ59
Hidrosmin C05CA05 C05CA05 C05CA05 C05CA05
Escin (=Aescin) 1 C05CA07 C05CA07 C05CA07 C05CA07
Vincamine-Rutoside C05CA51 C05CA51 C05CA51 C05CA51
Troxerutin-Vincamine C05CA54 C05CA54 C05CA54 C05CA54
Escin (=Aescin) 2 C05CA57 C05CA57 C05CA57 C05CA57
Dihydroergotaminmesilat 1 C06AA02 C06AA02 C06AA02 C06AA02
Dihydroergotaminmesilat 2 C06AA50 C06AA50 C06AA50 C06AA50
Oxprenolol 1 C07AA02 C07AA02 C07AA02 C07AA02
Pindolol 1 C07AA03 C07AA03 C07AA03 C07AA03
Propranolol 1 C07AA05 C07AA05 C07AA05 C07AA05
Sotalol 1 C07AA07 C07AA07 C07AA07 C07AA07
Nadolol 1 C07AA12 C07AA12 C07AA12 C07AA12
Sotalol 2 C07AA57 C07AA57 C07AA57 C07AA57
Labetalol 1 C07AG01 C07AG01 C07AG01 C07AG01
Oxprenolol 2 C07BA02 C07BA02 C07BA02 C07BA02
Propranolol 5 C07BA05 C07BA05 C07BA05 C07BA05
Sotalol 3 C07BA07 C07BA07 C07BA07 C07BA07
Nadolol 2 C07BA12 C07BA12 C07BA12 C07BA12
Labetalol 3 C07BG01 C07BG01 C07BG01 C07BG01
Oxprenolol 3 C07CA02 C07CA02 C07CA02 C07CA02
Pindolol 2 C07CA03 C07CA03 C07CA03 C07CA03
Propranolol 4 C07CA05 C07CA05 C07CA05 C07CA05
Labetalol 2 C07CG01 C07CG01 C07CG01 C07CG01
Propranolol 2 C07DA05 C07DA05 C07DA05 C07DA05
Pindolol 3 C07EA03 C07EA03 C07EA03 C07EA03
Propranolol 6 C07EA05 C07EA05 C07EA05 C07EA05
Oxprenolol 4 C07FA02 C07FA02 C07FA02 C07FA02
Propranolol 3 C07FA05 C07FA05 C07FA05 C07FA05
Nifedipine 4 C07FB22 C07FB22 C07FB22 C07FB22
Nifedipine 5 C07FB23 C07FB23 C07FB23 C07FB23
Nicardipine C08CA04 C08CA04 C08CA04 C08CA04
Nifedipine 1 C08CA05 C08CA05 C08CA05 C08CA05
Nifedipine 2 C08CA55 C08CA55 C08CA55 C08CA55
Verapamil 1 C08DA01 C08DA01 C08DA01 C08DA01
Verapamil 5 C08DA51 C08DA51 C08DA51 C08DA51
Verapamil 2 C08DA81 C08DA81 C08DA81 C08DA81
Diltiazem C08DB01 C08DB01 C08DB01 C08DB01
Nifedipine 3 C08GA01 C08GA01 C08GA01 C08GA01
Verapamil 3 C08GA02 C08GA02 C08GA02 C08GA02
Verapamil 4 C09BB10 C09BB10 C09BB10 C09BB10
Niacin (=Nicotinic acid) 1 C10AD02 C10AD02 C10AD02 C10AD02
Niacin (=Nicotinic acid) 3 C10AD52 C10AD52 C10AD52 C10AD52
Niacin (=Nicotinic acid) 4 C10BA01 C10BA01 C10BA01 C10BA01
Niacin (=Nicotinic acid) 5 C10BB01 C10BB01 C10BB01 C10BB01
Dimetindene 2 D04AA13 D04AA13 D04AA13 D04AA13
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Bromocriptine 2 G02CB01 G02CB01 G02CB01 G02CB01
Cabergoline 2 G02CB03 G02CB03 G02CB03 G02CB03
Oestrogen (oral) 1 G03CA01 G03CA01 G03CA01 G03CA01
Oestrogen (oral) 2 G03CA03 G03CA03 G03CA03 G03CA03
Oestrogen (oral) 3 G03CA04 G03CA04 G03CA04 G03CA04
Oestrogen (oral) 4 G03CA06 G03CA06 G03CA06 G03CA06
Oestrogen (oral) 5 G03CA07 G03CA07 G03CA07 G03CA07
Oestrogen (oral) 6 G03CA09 G03CA09 G03CA09 G03CA09
Oestrogen (oral) 7 G03CA10 G03CA10 G03CA10 G03CA10
Oestrogen (oral) 8 G03CA53 G03CA53 G03CA53 G03CA53
Oestrogen (oral) 9 G03CA57 G03CA57 G03CA57 G03CA57
Oestrogen (oral) 10 G03CB01 G03CB01 G03CB01 G03CB01
Oestrogen (oral) 11 G03CB02 G03CB02 G03CB02 G03CB02
Oestrogen (oral) 12 G03CB03 G03CB03 G03CB03 G03CB03
Oestrogen (oral) 13 G03CB04 G03CB04 G03CB04 G03CB04
Oestrogen (oral) 14 G03CC02 G03CC02 G03CC02 G03CC02
Oestrogen (oral) 15 G03CC03 G03CC03 G03CC03 G03CC03
Oestrogen (oral) 16 G03CC04 G03CC04 G03CC04 G03CC04
Oestrogen (oral) 17 G03CC05 G03CC05 G03CC05 G03CC05
Oestrogen (oral) 18 G03CC06 G03CC06 G03CC06 G03CC06
Oestrogen (oral) 19 G03CC07 G03CC07 G03CC07 G03CC07
Oestrogen (oral) 20 G03CC08 G03CC08 G03CC08 G03CC08
Oestrogen (oral) 21 G03CX01 G03CX01 G03CX01 G03CX01
Flavoxat G04BD02 G04BD02 G04BD02 G04BD02
Oxybutynine G04BD04 G04BD04 G04BD04 G04BD04
Tolterodine G04BD07 G04BD07 G04BD07 G04BD07
Solifenacin 1 G04BD08 G04BD08 G04BD08 G04BD08 
Trospium 1 G04BD09 G04BD09 G04BD09 G04BD09
Darifenacin G04BD10 G04BD10 G04BD10 G04BD10
Fesoterodin G04BD11 G04BD11 G04BD11 G04BD11
Trospium 5 G04BD59 G04BD59 G04BD59 G04BD59
Moxisylyte 2 G04BE06 G04BE06 G04BE06 G04BE06
Magnesium hydroxide 3 G04BX01 G04BX01 G04BX01 G04BX01
Terazosin 1 G04CA03 G04CA03 G04CA03 G04CA03
Doxazosin 2 G04CA05 G04CA05 G04CA05 G04CA05
Solifenacin 2 G04CA53 n/a n/a n/a
Ofloxacin J01MA01 J01MA01 J01MA01 J01MA01
Amantadine 2 J05AC04 J05AC04 J05AC04 J05AC04
Demecolcin L01CC01 L01CC01 L01CC01 L01CC01
Celecoxib 2 L01XX33 L01XX33 L01XX33 L01XX33
Phenylbutazone 1 M01AA01 M01AA01 M01AA01 M01AA01 
Phenylbutazone 2 M01AA51 M01AA51 M01AA51 M01AA51
Indometacin 1 M01AB01 M01AB01 M01AB01 M01AB01
Diclofenac 1 M01AB05 M01AB05 M01AB05 M01AB05
Acemetacin M01AB11 M01AB11 M01AB11 M01AB11
Ketorolac M01AB15  M01AB15  M01AB15  M01AB15  
Aceclofenac 1 M01AB16 M01AB16 M01AB16 M01AB16
Indometacin 3 M01AB51 M01AB51 M01AB51 M01AB51
Diclofenac 2 M01AB55 M01AB55 M01AB55 M01AB55
Piroxicam 1 M01AC01 M01AC01 M01AC01 M01AC01 
Lornoxicam M01AC05 M01AC05 M01AC05 M01AC05
Meloxicam 1 M01AC06 M01AC06 M01AC06 M01AC06
Meloxicam 2 M01AC56 M01AC56 n/a n/a
Ketoprofen 1 M01AE03 M01AE03 M01AE03 M01AE03 
Flurbiprofen 1 M01AE09 M01AE09 M01AE09 M01AE09
Dexketoprofen M01AE17 M01AE17 M01AE17 M01AE17
Ketoprofen 2 M01AE53 M01AE53 M01AE53 M01AE53
Mefenamic acid M01AG01 M01AG01 M01AG01 M01AG01
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Celecoxib 1 M01AH01 M01AH01 M01AH01 M01AH01
Etoricoxib M01AH05 M01AH05 M01AH05 M01AH05
Nabumetone M01AX01 M01AX01 M01AX01 M01AX01
Phenylbutazone 3 M01BA01 M01BA01 M01BA01 M01BA01
Phenylbutazone 5 M02AA01 M02AA01 M02AA01 M02AA01
Piroxicam 2 M02AA07 M02AA07 M02AA07 M02AA07
Ketoprofen 3 M02AA10 M02AA10 M02AA10 M02AA10
Diclofenac 3 M02AA15 M02AA15 M02AA15 M02AA15
Flurbiprofen 2 M02AA19 M02AA19 M02AA19 M02AA19
Indometacin 4 M02AA23 M02AA23 M02AA23 M02AA23
Aceclofenac 2 M02AA25 M02AA25 M02AA25 M02AA25
Indometacin 5 M02AA73 M02AA73 M02AA73 M02AA73
Niacin (=Nicotinic acid) 6 M02AD50 M02AD50 M02AD50 M02AD50
Carisoprodol 1 M03BA02 M03BA02 M03BA02 M03BA02
Methocarbamol 1 M03BA03 M03BA03 M03BA03 M03BA03
Carisoprodol 2 M03BA52 M03BA52 M03BA52 M03BA52
Methocarbamol 2 M03BA53 M03BA53 M03BA53 M03BA53
Meprobamate 4 M03BA57 M03BA57 M03BA57 M03BA57
Carisoprodol 3 M03BA72 M03BA72 M03BA72 M03BA72
Methocarbamol 3 M03BA73 M03BA73 M03BA73 M03BA73
Orphenadrine 1 M03BC01 M03BC01 M03BC01 M03BC01
Orphenadrine 2 M03BC51 M03BC51 M03BC51 M03BC51
Baclofen M03BX01 M03BX01 M03BX01 M03BX01
Tizanidine M03BX02 M03BX02 M03BX02 M03BX02
Tetrazepam M03BX07 M03BX07 M03BX07 M03BX07
Cyclobenzaprine M03BX08 M03BX08 M03BX08 M03BX08
Colchicin M04AC01 M04AC01 M04AC01 M04AC01
Strontium ranelate M05BX03 M05BX03 M05BX03 M05BX03
Quinine and derivatives 1 M09AA01 M09AA01 M09AA01 M09AA01
Quinine and derivatives 2 M09AA02 M09AA02 M09AA02 M09AA02
Quinine and derivatives 3 M09AA52 M09AA52 M09AA52 M09AA52
Quinine and derivatives 4 M09AA72 M09AA72 M09AA72 M09AA72
Diphenhydramine 4 N01BX06 N01BX06 N01BX06 N01BX06
Ethylmorphine 2 N02AA57 N02AA57 N02AA57 N02AA57
Diclofenac 4 N02AA65 N02AA65 N02AA65 N02AA65
Pethidine (=Meperidine) 1 N02AB02 N02AB02 N02AB02 N02AB02
Pethidine (=Meperidine) 2 N02AB52 N02AB52 N02AB52 N02AB52
Pethidine (=Meperidine) 3 N02AB72 N02AB72 N02AB72 N02AB72
Methadone 3 (Levomethadone) N02AC06 N02AC06 N02AC06 N02AC06
Methadone 2 N02AC52 N02AC52 N02AC52 N02AC52
Pentazocine N02AD01 N02AD01 N02AD01 N02AD01
Pethidine (=Meperidine) 4 N02AG03 N02AG03 N02AG03 N02AG03
Tramadol 1 N02AX02 N02AX02 N02AX02 N02AX02
Tramadol 2 N02AX52 N02AX52 N02AX52 N02AX52
Dihydroergotamine 1 N02CA01 N02CA01 N02CA01 N02CA01
Ergotamine 1 N02CA02 N02CA02 N02CA02 N02CA02
Dihydroergotamine 2 N02CA51 N02CA51 N02CA51 N02CA51
Ergotamine 2 N02CA52 N02CA52 N02CA52 N02CA52
Dihydroergotamine 3 N02CA71 N02CA71 N02CA71 N02CA71
Ergotamine 3 N02CA72 N02CA72 N02CA72 N02CA72
Triptanes / Selektive Serotonin-5HT1-Agonisten 1 N02CC01 N02CC01 N02CC01 N02CC01
Triptanes / Selektive Serotonin-5HT1-Agonisten 2 N02CC02 N02CC02 N02CC02 N02CC02
Triptanes / Selektive Serotonin-5HT1-Agonisten 3 N02CC03 N02CC03 N02CC03 N02CC03
Triptanes / Selektive Serotonin-5HT1-Agonisten 4 N02CC04 N02CC04 N02CC04 N02CC04
Triptanes / Selektive Serotonin-5HT1-Agonisten 5 N02CC05 N02CC05 N02CC05 N02CC05
Triptanes / Selektive Serotonin-5HT1-Agonisten 6 N02CC06 N02CC06 N02CC06 N02CC06
Triptanes / Selektive Serotonin-5HT1-Agonisten 7 N02CC07 N02CC07 N02CC07 N02CC07
Clonidine 4 N02CX02 N02CX02 N02CX02 N02CX02
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Topiramate 2 N02CX12 N02CX12 N02CX12 N02CX12
Metoclopramide 3 N02CX59 N02CX59 N02CX59 N02CX59
Phenobarbital 1 N03AA02 N03AA02 N03AA02 N03AA02
Phenytoin 1 N03AB02 N03AB02 N03AB02 N03AB02
Phenytoin 3 (Fosphenytoin) N03AB05 N03AB05 N03AB05 N03AB05
Phenytoin 2 N03AB52 N03AB52 N03AB52 N03AB52
Clonazepam N03AE01 N03AE01 N03AE01 N03AE01
Midazolam 2 N03AE02 N03AE02 n/a n/a
Carbamazepine N03AF01 N03AF01 N03AF01 N03AF01
Topiramate 1 N03AX11 N03AX11 N03AX11 N03AX11
Trihexyphenidyl N04AA01 N04AA01 N04AA01 N04AA01
Biperiden N04AA02 N04AA02 N04AA02 N04AA02
Tropatepin N04AA12 N04AA12 N04AA12 N04AA12 
Orphenadrine 3 N04AB02 N04AB02 N04AB02 N04AB02
Benzatropine 1 N04AC01 N04AC01 N04AC01 N04AC01
Benzatropine 2 (Etybenzatropin) N04AC30 N04AC30 N04AC30 N04AC30
Amantadine 1 N04BB01 N04BB01 N04BB01 N04BB01
Bromocriptine 1 N04BC01 N04BC01 N04BC01 N04BC01
Pergolide N04BC02 N04BC02 N04BC02 N04BC02
Dihydroergocryptine N04BC03 N04BC03 N04BC03 N04BC03
Ropinirole N04BC04 N04BC04 N04BC04 N04BC04
Pramipexole N04BC05 N04BC05 N04BC05 N04BC05
Cabergoline 1 N04BC06 N04BC06 N04BC06 N04BC06
Piribedil 1 N04BC08 N04BC08 N04BC08 N04BC08
Rotigotine N04BC09 N04BC09 N04BC09 N04BC09
Selegiline N04BD01 N04BD01 N04BD01 N04BD01
Chlorpromazine N05AA01 N05AA01 N05AA01 N05AA01 
Levomepromazine N05AA02 N05AA02 N05AA02 N05AA02
Clorazepate-Acepromazine 1 N05AA04           N05AA04                N05AA04                 N05AA04        
Cyamemazine N05AA06 N05AA06 N05AA06 N05AA06
Fluphenazine N05AB02 N05AB02 N05AB02 N05AB02
Perphenazine N05AB03 N05AB03 N05AB03 N05AB03
Prochlorperazine N05AB04 N05AB04 N05AB04 N05AB04
Trifluoperazine N05AB06 N05AB06 N05AB06 N05AB06
Propericiazine (=Periciazine) N05AC01 N05AC01 N05AC01 N05AC01
Thioridazine N05AC02 N05AC02 N05AC02 N05AC02
Pipotiazine N05AC04 N05AC04 N05AC04 N05AC04
Droperidol N05AD08 N05AD08 N05AD08 N05AD08
Sertindole N05AE03 N05AE03 N05AE03 N05AE03
Ziprasidone N05AE04 N05AE04 N05AE04 N05AE04
Flupentixole N05AF01 N05AF01 N05AF01 N05AF01
Chlorprothixen N05AF03 N05AF03 N05AF03 N05AF03
Zuclopenthixol N05AF05 N05AF05 N05AF05 N05AF05
Pimozide N05AG02 N05AG02 N05AG02 N05AG02
Clozapine N05AH02 N05AH02 N05AH02 N05AH02
Lithium N05AN01 N05AN01 N05AN01 N05AN01
Aripiprazole N05AX12 N05AX12 N05AX12 N05AX12
Reserpine 6 N05AX15 N05AX15 N05AX15 N05AX15
Diazepam N05BA01 N05BA01 N05BA01 N05BA01
Chlordiazepoxide N05BA02 N05BA02 N05BA02 N05BA02
Medazepam N05BA03 N05BA03 N05BA03 N05BA03
Clorazepate-Acepromazine 2 (Dipotassium clorazepate) N05BA05 N05BA05 N05BA05 N05BA05
Bromazepam N05BA08 N05BA08 N05BA08 N05BA08
Clobazam N05BA09 N05BA09 N05BA09 N05BA09
Prazepam N05BA11 N05BA11 N05BA11 N05BA11
Alprazolam N05BA12 N05BA12 N05BA12 N05BA12
Halazepam N05BA13 N05BA13 N05BA13 N05BA13
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Nordazepam N05BA16 N05BA16 N05BA16 N05BA16
(Ethyl-) Loflazepate N05BA18 N05BA18 N05BA18 N05BA18 
Hydroxyzine 1 N05BB01 N05BB01 N05BB01 N05BB01
Hydroxyzine 3 N05BB51 N05BB51 N05BB51 N05BB51
Meprobamate 1 N05BC01 N05BC01 N05BC01 N05BC01
Meprobamate 2 N05BC51 N05BC51 N05BC51 N05BC51
Phenobarbital 2 N05CA24 N05CA24 N05CA24 N05CA24
Chloralhydrate 1 N05CC01 N05CC01 N05CC01 N05CC01 
Flurazepam N05CD01 N05CD01 N05CD01 N05CD01
Nitrazepam N05CD02 N05CD02 N05CD02 N05CD02
Flunitrazepam N05CD03 N05CD03 N05CD03 N05CD03
Estazolam N05CD04 N05CD04 N05CD04 N05CD04 
Triazolam N05CD05 N05CD05 N05CD05 N05CD05
Temazepam N05CD07 N05CD07 N05CD07 N05CD07
Midazolam 1 N05CD08 N05CD08 N05CD08 N05CD08
Quazepam N05CD10 N05CD10 N05CD10 N05CD10
Clomethiazole 1 N05CM02 N05CM02 N05CM02 N05CM02
Scopolamine 3 (=Hyoscin) N05CM05 N05CM05 N05CM05 N05CM05
Propiomazine N05CM06 N05CM06 N05CM06 N05CM06
Diphenhydramine 5 N05CM20 N05CM20 N05CM20 N05CM20
Doxylamine 3 N05CM21 N05CM21 N05CM21 N05CM21
Promethazine 4 N05CM22 N05CM22 N05CM22 N05CM22
Meprobamate 3 N05CX01 N05CX01 N05CX01 N05CX01
Clomethiazole 2 N05CX04 N05CX04 N05CX04 N05CX04
Diphenhydramine 2 N05CX07 N05CX07 N05CX07 N05CX07
Chloralhydrate 2 N05CX11 N05CX11 N05CX11 N05CX11
Promethazine 5 N05CX13 N05CX13 N05CX13 N05CX13
Desipramine N06AA01 N06AA01 N06AA01 N06AA01
Imipramine 1 N06AA02 N06AA02 N06AA02 N06AA02
Imipramine 2 N06AA03 N06AA03 N06AA03 N06AA03
Clomipramine N06AA04 N06AA04 N06AA04 N06AA04
Trimipramine N06AA06 N06AA06 N06AA06 N06AA06
Amitriptyline 1 N06AA09 N06AA09 N06AA09 N06AA09
Nortriptyline 1 N06AA10 N06AA10 N06AA10 N06AA10
Doxepin N06AA12 N06AA12 N06AA12 N06AA12
Dosulepin 1 N06AA16 N06AA16 N06AA16 N06AA16
Amoxapine N06AA17 N06AA17 N06AA17 N06AA17
Maprotiline N06AA21 N06AA21 N06AA21 N06AA21
Amitriptyline 3 N06AA25 N06AA25 N06AA25 N06AA25
Fluoxetine 1 N06AB03 N06AB03 N06AB03 N06AB03
Paroxetine N06AB05 N06AB05 N06AB05 N06AB05
Fluvoxamine N06AB08 N06AB08 N06AB08 N06AB08
Tranylcypromine 1 N06AF04 N06AF04 N06AF04 N06AF04
Bupropion 1 N06AX12 N06AX12 N06AX12 N06AX12
Venlafaxine 1 N06AX16 N06AX16 N06AX16 N06AX16
Reboxetine N06AX18 N06AX18 N06AX18 N06AX18
Venlafaxine 2 (Desvenlafaxine) N06AX23 N06AX23 N06AX23 N06AX23
Methylphenidat N06BA04 N06BA04 N06BA04 N06BA04
Piracetam N06BX03 N06BX03 N06BX03 N06BX03
Amitriptyline 2 N06CA01 N06CA01 N06CA01 N06CA01
Fluoxetine 2 N06CA03 n/a n/a n/a
Nortriptyline 2 N06CA06 N06CA06 N06CA06 N06CA06
Tranylcypromine 2 N06CA07 N06CA03 N06CA03 N06CA03
Dosulepin 2 N06CA10 N06CA10 N06CA10 N06CA10
Ginkgo biloba N06DP01 N06DP01 N06DP01 N06DH01
Ergoloid mesylate (= dihydroergotoxine) 4 N06DX07 N06DX07 N06DX07 N06DX07
Vincamine 2 N06DX09 N06DX09 N06DX09 N06DX09
Nicergoline 2 N06DX13 N06DX13 N06DX13 N06DX13
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Cyclandelate (=Cyclospasmol) 2 N06DX14 N06DX14 N06DX14 N06DX14
Dihydroergocristine 3 N06DX19 N06DX19 N06DX19 N06DX19
Ergoloid mesylate (= dihydroergotoxine) 3 N06DX57 N06DX57 N06DX57 N06DX57
Bethanechol N07AB02 N07AB02 N07AB02 N07AB02
Bupropion 2 N07BA02 N07BA02 N07BA02 N07BA02
Clonidine 5 N07BB06 N07BB06 N07BB06 N07BB06
Methadone 1 N07BC02 N07BC02 N07BC02 N07BC02
Dextrometorphan 2 N07XX59 n/a n/a n/a
Quinine and derivatives 7 P01BC01 P01BC01 P01BC01 P01BC01
Norephedrine (=Phenylpropanolamine) 1 R01BA01 R01BA01 R01BA01 R01BA01
Pseudoephedrine 1 R01BA02 R01BA02 R01BA02 R01BA02
Norephedrine (=Phenylpropanolamine) 2 R01BA51 R01BA51 R01BA51 R01BA51
Pseudoephedrine 2 R01BA52 R01BA52 R01BA52 R01BA52
Flurbiprofen 3 R02AX01 R02AX01 R02AX01 R02AX01
Terbutaline (oral) 2 R03AC03 R03AC03 R03AC03 R03AC03
Terbutaline (oral) 1 R03CC03 R03CC03 R03CC03 R03CC03
Terbutaline (oral) 3 R03CC53 R03CC53 R03CC53 R03CC53
Theophylline 1 R03DA04 R03DA04 R03DA04 R03DA04
Theophylline 4 R03DA54 R03DA54 R03DA54 R03DA54
Theophylline 5 R03DA74 R03DA74 R03DA74 R03DA74
Theophylline 6 R03DB04 R03DB04 R03DB04 R03DB04
Ethylmorphine 1 R05DA01 R05DA01 R05DA01 R05DA01
Dextrometorphan 1 R05DA09 R05DA09 R05DA09 R05DA09
Dextrometorphan 3 R05DA59 R05DA59 R05DA59 R05DA59
Phenylbutazone 4 R05XA10 R05XA10 R05XA10 R05XA10
Diphenhydramine 1 R06AA02 R06AA02 R06AA02 R06AA02
Clemastine 1 R06AA04 R06AA04 R06AA04 R06AA04
Carbinoxamine R06AA08  R06AA08  R06AA08  R06AA08  
Doxylamine 1 R06AA09 R06AA09 R06AA09 R06AA09
Diphenhydramine 7 R06AA52 R06AA52 R06AA52 R06AA52
Clemastine 2 R06AA54 R06AA54 R06AA54 R06AA54
Doxylamine 2 R06AA59 R06AA59 n/a n/a
Brompheniramine 1 R06AB01 R06AB01 R06AB01 R06AB01
Dexchlorpheniramine 1 R06AB02 R06AB02 R06AB02 R06AB02
Dimetindene 1 R06AB03 R06AB03 R06AB03 R06AB03
Chlorpheniramine (=Chlorphenamine) 1 R06AB04 R06AB04 R06AB04 R06AB04
Pheniramine R06AB05 R06AB05 R06AB05 R06AB05
Dexbrompheniramin 1 R06AB06 R06AB06 R06AB06 R06AB06
Brompheniramine 2 R06AB51 R06AB51 R06AB51 R06AB51
Dexchlorpheniramine 2 R06AB52 R06AB52 R06AB52 R06AB52
Chlorpheniramine (=Chlorphenamine) 2 R06AB54 R06AB54 R06AB54 R06AB54
Dexbrompheniramin 2 R06AB56 R06AB56 R06AB56 R06AB56
Tripelennamine R06AC04 R06AC04 R06AC04 R06AC04
Alimemazine R06AD01 R06AD01 R06AD01 R06AD01 
Promethazine 1 R06AD02 R06AD02 R06AD02 R06AD02
Promethazine 8 (Hydroxyethylpromethazin 1) R06AD05 R06AD05 R06AD05 R06AD05
Mequitazine R06AD07 R06AD07 R06AD07 R06AD07
Oxomemazine R06AD08 R06AD08 R06AD08 R06AD08
Promethazine 7 (Dioxopromethazin) R06AD10 R06AD10 R06AD10 R06AD10
Promethazine 2 R06AD52 R06AD52 R06AD52 R06AD52
Promethazine 9 (Hydroxyethylpromethazin 2) R06AD55 R06AD55 R06AD55 R06AD55
Buclizine 1 R06AE01 R06AE01 R06AE01 R06AE01 
Cyclizine 1 R06AE03 R06AE03 R06AE03 R06AE03
Meclozine 1 R06AE05  R06AE05  R06AE05  R06AE05  
Buclizine 2 R06AE51 R06AE51 R06AE51 R06AE51
Cyclizine 2 R06AE53 R06AE53 R06AE53 R06AE53
Meclozine 2 R06AE55 R06AE55 R06AE55 R06AE55
Cyproheptadine 1 R06AX02 R06AX02 R06AX02 R06AX02
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Triprolidine 1 R06AX07 R06AX07 R06AX07 R06AX07
Terfenadine R06AX12 R06AX12 R06AX12 R06AX12
Ebastine R06AX22 R06AX22 R06AX22 R06AX22
Pimethixene R06AX23 R06AX23 R06AX23 R06AX23 
Hydroxyzine 2 R06AX32 R06AX32 R06AX32 R06AX32
Triprolidine 2 R06AX57 R06AX57 R06AX57 R06AX57
Promethazine 6 V03AB05 V03AB05 V03AB05 V03AB05
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PRICSCUS List
ATC-Code 
2014
ATC-Code 
2013
ATC-Code 
2012
ATC-Code 
2011
Acemetacin M01AB11 M01AB11 M01AB11 M01AB11
Acetyldigoxin 1 C01AA02 C01AA02 C01AA02 C01AA02
Acetyldigoxin 2 C01AA52 C01AA52 C01AA52 C01AA52
Alprazolam N05BA12 N05BA12 N05BA12 N05BA12
Amitriptyline 1 N06AA09 N06AA09 N06AA09 N06AA09
Amitriptyline 2 N06CA01 N06CA01 N06CA01 N06CA01
Amitriptyline 3 N06AA25 N06AA25 N06AA25 N06AA25
Baclofen M03BX01 M03BX01 M03BX01 M03BX01
Bromazepam N05BA08 N05BA08 N05BA08 N05BA08
Chinidin = Quinidine 1 C01BA01 C01BA01 C01BA01 C01BA01
Chinidin = Quinidine 2 C01BA51 C01BA51 C01BA51 C01BA51
Chinidin = Quinidine 3 C01BA71 C01BA71 C01BA71 C01BA71
Chloralhydrat 1 N05CC01 N05CC01 N05CC01 N05CC01 
Chloralhydrat 2 N05CX11 N05CX11 N05CX11 N05CX11
Chlordiazepoxid N05BA02 N05BA02 N05BA02 N05BA02
Chlorpheniramine (=Chlorphenamine) 1 R06AB04 R06AB04 R06AB04 R06AB04
Chlorpheniramine (=Chlorphenamine) 2 R06AB54 R06AB54 R06AB54 R06AB54
Clemastin 1 R06AA04 R06AA04 R06AA04 R06AA04
Clemastin 2 R06AA54 R06AA54 R06AA54 R06AA54
Clobazam N05BA09 N05BA09 N05BA09 N05BA09
Clomipramin N06AA04 N06AA04 N06AA04 N06AA04
Clonidin 1 C02AC01 C02AC01 C02AC01 C02AC01
Clonidin 2 C02LC01 C02LC01 C02LC01 C02LC01
Clonidin 3 C02LC51 C02LC51 C02LC51 C02LC51
Clonidin 4 N02CX02 N02CX02 N02CX02 N02CX02
Clonidin 5 N07BB06 N07BB06 N07BB06 N07BB06
Clozapin N05AH02 N05AH02 N05AH02 N05AH02
Diazepam N05BA01 N05BA01 N05BA01 N05BA01
Dickflüssiges Paraffin 1 A06AA01 A06AA01 A06AA01 A06AA01
Dickflüssiges Paraffin 2 A06AA51 A06AA51 A06AA51 A06AA51
Digoxin 1 C01AA05 C01AA05 C01AA05 C01AA05
Digoxin 2 C01AA55 C01AA55 C01AA55 C01AA55
Dihydroergocryptinmesilat N04BC03 N04BC03 N04BC03 N04BC03
Dihydroergotamin 1 N02CA01 N02CA01 N02CA01 N02CA01
Dihydroergotamin 2 N02CA51 N02CA51 N02CA51 N02CA51
Dihydroergotamin 3 N02CA71 N02CA71 N02CA71 N02CA71
Dihydroergotaminmesilat 1 C06AA02 C06AA02 C06AA02 C06AA02
Dihydroergotaminmesilat 2 C06AA50 C06AA50 C06AA50 C06AA50
Dihydroergotoxin 1 N06DX07 N06DX07 N06DX07 N06DX07
Dihydroergotoxin 2 N06DX57 N06DX57 N06DX57 N06DX57
Dikaliumclorazepat N05BA05 N05BA05 N05BA05 N05BA05
Dimenhydrinate 1 A04AB02 A04AB02 A04AB02 A04AB02
Dimenhydrinate 2 A04AB52 A04AB52 A04AB52 A04AB52
Dimetindene 1 R06AB03 R06AB03 R06AB03 R06AB03
Dimetindene 2 D04AA13 D04AA13 D04AA13 D04AA13
Diphenhydramine 1 R06AA02 R06AA02 R06AA02 R06AA02
Diphenhydramine 2 N05CX07 N05CX07 N05CX07 N05CX07
Diphenhydramine 3 A04AB05 A04AB05 A04AB05 A04AB05
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Diphenhydramine 4 N01BX06 N01BX06 N01BX06 N01BX06
Diphenhydramine 5 N05CM20 N05CM20 N05CM20 N05CM20
Diphenhydramine 6 A04AB55 A04AB55 A04AB55 A04AB55
Diphenhydramine 7 R06AA52 R06AA52 R06AA52 R06AA52
Doxazosin 1 C02CA04 C02CA04 C02CA04 C02CA04
Doxazosin 2 G04CA05 G04CA05 G04CA05 G04CA05
Doxepin N06AA12 N06AA12 N06AA12 N06AA12
Doxylamine 1 R06AA09 R06AA09 R06AA09 R06AA09
Doxylamine 2 R06AA59 R06AA59 n/a n/a
Doxylamine 3 N05CM21 N05CM21 N05CM21 N05CM21
Doxylamine 4 A04AB56 A04AB56 A04AB56 A04AB56
Ergotamine 1 N02CA02 N02CA02 N02CA02 N02CA02
Ergotamine 2 N02CA52 N02CA52 N02CA52 N02CA52
Ergotamine 3 N02CA72 N02CA72 N02CA72 N02CA72
Etoricoxib M01AH05 M01AH05 M01AH05 M01AH05
Flecainid C01BC04 C01BC04 C01BC04 C01BC04
Flunitrazepam N05CD03 N05CD03 N05CD03 N05CD03
Fluoxetine 1 N06AB03 N06AB03 N06AB03 N06AB03
Fluoxetine 2 N06CA03 n/a n/a n/a
Fluphenazin N05AB02 N05AB02 N05AB02 N05AB02
Flurazepam N05CD01 N05CD01 N05CD01 N05CD01
Hydroxyzine 1 N05BB01 N05BB01 N05BB01 N05BB01
Hydroxyzine 2 R06AX32 R06AX32 R06AX32 R06AX32
Hydroxyzine 3 N05BB51 N05BB51 N05BB51 N05BB51
Imipramin N06AA02 N06AA02 N06AA02 N06AA02
Imipraminoxid N06AA03 N06AA03 N06AA03 N06AA03
Indometacin 1 M01AB01 M01AB01 M01AB01 M01AB01
Indometacin 2 C01EB03 C01EB03 C01EB03 C01EB03
Indometacin 3 M01AB51 M01AB51 M01AB51 M01AB51
Indometacin 4 M02AA23 M02AA23 M02AA23 M02AA23
Indometacin 5 M02AA73 M02AA73 M02AA73 M02AA73
Ketoprofen 1 M01AE03 M01AE03 M01AE03 M01AE03 
Ketoprofen 2 M01AE53 M01AE53 M01AE53 M01AE53
Ketoprofen 3 M02AA10 M02AA10 M02AA10 M02AA10
Levomepromazin N05AA02 N05AA02 N05AA02 N05AA02
Maprotilin N06AA21 N06AA21 N06AA21 N06AA21
Medazepam N05BA03 N05BA03 N05BA03 N05BA03
Meloxicam 1 M01AC06 M01AC06 M01AC06 M01AC06
Meloxicam 2 M01AC56 M01AC56 n/a n/a
Methyldopa 1 C02AB01 C02AB01 C02AB01 C02AB01
Methyldopa 2 C02AB02 C02AB02 C02AB02 C02AB02
Methyldopa 3 C02LB01 C02LB01 C02LB01 C02LB01
Metildigoxin 1 C01AA08 C01AA08 C01AA08 C01AA08
Metildigoxin 2 C01AA58 C01AA58 C01AA58 C01AA58
Naftidrofuryl C04AX21 C04AX21 C04AX21 C04AX21
Nicergoline 1 C04AE02 C04AE02 C04AE02 C04AE02
Nicergoline 2 N06DX13 N06DX13 N06DX13 N06DX13
Nifedipine 1 C08CA05 C08CA05 C08CA05 C08CA05
Nifedipine 2 C08CA55 C08CA55 C08CA55 C08CA55
Nifedipine 3 C08GA01 C08GA01 C08GA01 C08GA01
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Nifedipine 4 C07FB22 C07FB22 C07FB22 C07FB22
Nifedipine 5 C07FB23 C07FB23 C07FB23 C07FB23
Nitrazepam N05CD02 N05CD02 N05CD02 N05CD02
Nitrofurantoin 1 J01XE01 J01XE01 J01XE01 J01XE01
Nitrofurantoin 2 J01XE51 J01XE51 J01XE51 J01XE51
Oxybutynin G04BD04 G04BD04 G04BD04 G04BD04
Pentoxifyllin C04AD03 C04AD03 C04AD03 C04AD03
Perphenazin N05AB03 N05AB03 N05AB03 N05AB03
Pethidine (=Meperidine) 1 N02AB02 N02AB02 N02AB02 N02AB02
Pethidine (=Meperidine) 2 N02AB52 N02AB52 N02AB52 N02AB52
Pethidine (=Meperidine) 3 N02AB72 N02AB72 N02AB72 N02AB72
Pethidine (=Meperidine) 4 N02AG03 N02AG03 N02AG03 N02AG03
Phenobarbital 1 N03AA02 N03AA02 N03AA02 N03AA02
Phenobarbital 2 N05CA24 N05CA24 N05CA24 N05CA24
Phenylbutazone 1 M01AA01 M01AA01 M01AA01 M01AA01 
Phenylbutazone 2 M01AA51 M01AA51 M01AA51 M01AA51
Phenylbutazone 3 M01BA01 M01BA01 M01BA01 M01BA01
Phenylbutazone 4 R05XA10 R05XA10 R05XA10 R05XA10
Phenylbutazone 5 M02AA01 M02AA01 M02AA01 M02AA01
Piracetam N06BX03 N06BX03 N06BX03 N06BX03
Piroxicam 1 M01AC01 M01AC01 M01AC01 M01AC01 
Piroxicam 2 M02AA07 M02AA07 M02AA07 M02AA07
Prasugrel B01AC22 B01AC22 B01AC22 B01AC22
Prazepam N05BA11 N05BA11 N05BA11 N05BA11
Prazosin 1 C02CA01 C02CA01 C02CA01 C02CA01
Prazosin 2 C02LE01 C02LE01 C02LE01 C02LE01
Reserpine 1 C02AA02 C02AA02 C02AA02 C02AA02
Reserpine 2 C02AA52 C02AA52 C02AA52 C02AA52
Reserpine 3 C02LA01 C02LA01 C02LA01 C02LA01
Reserpine 4 C02LA51 C02LA51 C02LA51 C02LA51
Reserpine 5 C02LA71 C02LA71 C02LA71 C02LA71
Reserpine 6 N05AX15 N05AX15 N05AX15 N05AX15
Solifenacin 1 G04BD08 G04BD08 G04BD08 G04BD08 
Solifenacin 2 G04CA53 n/a n/a n/a
Sotalol 1 C07AA07 C07AA07 C07AA07 C07AA07
Sotalol 2 C07AA57 C07AA57 C07AA57 C07AA57
Sotalol 3 C07BA07 C07BA07 C07BA07 C07BA07
Temazepam N05CD07 N05CD07 N05CD07 N05CD07
Terazosin 1 G04CA03 G04CA03 G04CA03 G04CA03
Terazosin 2 C02CA08 C02CA08 C02CA08 C02CA08
Tetrazepam M03BX07 M03BX07 M03BX07 M03BX07
Thioridazin N05AC02 N05AC02 N05AC02 N05AC02
Ticlopidin B01AC05 B01AC05 B01AC05 B01AC05
Tolterodin G04BD07 G04BD07 G04BD07 G04BD07
Tranylcypromine 1 N06AF04 N06AF04 N06AF04 N06AF04
Tranylcypromine 2 N06CA07 N06CA03 N06CA03 N06CA03
Triazolam N05CD05 N05CD05 N05CD05 N05CD05
Trimipramin N06AA06 N06AA06 N06AA06 N06AA06
Verapamil in Kombination mit Chinidin C08DA81 C08DA81 C08DA81 C08DA81
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Anticholinergic Drug Scale ATC-Code 
2014
ATC-Code 
2013
ATC-Code 
2012
ATC-Code 
2011
Score
Dexamethasone 2 A01AC02 A01AC02 A01AC02 A01AC02 1
Hydrocortisone 2 A01AC03 A01AC03 A01AC03 A01AC03 1
Cimetidine A02BA01 A02BA01 A02BA01 A02BA01 2
Ranitidine 1 A02BA02 A02BA02 A02BA02 A02BA02 2
Famotidine 1 A02BA03 A02BA03 A02BA03 A02BA03 1
Nizatidine A02BA04 A02BA04 A02BA04 A02BA04 1
Ranitidine 2 A02BA07 A02BA07 A02BA07 A02BA07 2
Famotidine 2 A02BA53 A02BA53 A02BA53 A02BA53 1
Omeprazole A02BC01 A02BC01 A02BC01 A02BC01 0
Pantoprazole A02BC02 A02BC02 A02BC02 A02BC02 0
Lansoprazole A02BC03 A02BC03 A02BC03 A02BC03 0
Rabeprazol A02BC04 A02BC04 A02BC04 A02BC04 0
Dicyclomine (=Dicycloverin) 1 A03AA07 A03AA07 A03AA07 A03AA07 3
Propantheline 1 A03AB05 A03AB05 A03AB05 A03AB05 3
Atropine 1 A03BA01 A03BA01 A03BA01 A03BA01 3
Hyoscyamine 1 A03BA03 A03BA03 A03BA03 A03BA03 3
Propantheline 2 A03CA34 A03CA34 A03CA34 A03CA34 3
Hyoscyamine 2 A03CB31 A03CB31 A03CB31 A03CB31 3
Metoclopramide 1 A03FA01 A03FA01 A03FA01 A03FA01 0
Metoclopramide 2 A03FA51 A03FA51 A03FA51 A03FA51 0
Dimenhydrinate 1 A04AB02 A04AB02 A04AB02 A04AB02 3
Meclozine 3 A04AB04 A04AB04 A04AB04 A04AB04 3
Diphenhydramine 3 A04AB05 A04AB05 A04AB05 A04AB05 3
Dimenhydrinate 2 A04AB52 A04AB52 A04AB52 A04AB52 3
Meclozine 4 A04AB54 A04AB54 A04AB54 A04AB54 3
Diphenhydramine 6 A04AB55 A04AB55 A04AB55 A04AB55 3
Promethazine 3 A04AB58 A04AB58 A04AB58 A04AB58 3
Scopolamine 1 (=Hyoscin) A04AD01 A04AD01 A04AD01 A04AD01 3
Scopolamine 2 (=Hyoscin) A04AD51 A04AD51 A04AD51 A04AD51 3
Bisacodyl A06AB02 A06AB02 A06AB02 A06AB02 0
Senna glycosides 1 A06AB06 A06AB06 A06AB06 A06AB06 0
Senna glycosides 2 A06AB56 A06AB56 A06AB56 A06AB56 0
Vancomycin 2 A07AA09 A07AA09 A07AA09 A07AA09 1
Diphenoxylate A07DA01 A07DA01 A07DA01 A07DA01 0
Loperamide 1 A07DA03 A07DA03 A07DA03 A07DA03 1
Morphine 2 A07DA52 A07DA52 A07DA52 A07DA52 1
Loperamide 2 A07DA53 A07DA53 A07DA53 A07DA53 1
Insulin 1 A10AB01 A10AB01 A10AB01 A10AB01 0
Insulin 2 A10AB02 A10AB02 A10AB02 A10AB02 0
Insulin 3 A10AB03 A10AB03 A10AB03 A10AB03 0
Insulin 4 A10AB04 A10AB04 A10AB04 A10AB04 0
Insulin 5 A10AB05 A10AB05 A10AB05 A10AB05 0
Insulin 6 A10AB06 A10AB06 A10AB06 A10AB06 0
Insulin 7 A10AB30 A10AB30 A10AB30 A10AB30 0
Insulin 8 A10AC01 A10AC01 A10AC01 A10AC01 0
Insulin 9 A10AC02 A10AC02 A10AC02 A10AC02 0
Insulin 10 A10AC03 A10AC03 A10AC03 A10AC03 0
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open
 doi: 10.1136/bmjopen-2020-039747:e039747. 10 2020;BMJ Open, et al. Müller BS
Insulin 11 A10AC04 A10AC04 A10AC04 A10AC04 0
Insulin 12 A10AC30 A10AC30 A10AC30 A10AC30 0
Insulin 13 A10AD01 A10AD01 A10AD01 A10AD01 0
Insulin 14 A10AD02 A10AD02 A10AD02 A10AD02 0
Insulin 15 A10AD03 A10AD03 A10AD03 A10AD03 0
Insulin 16 A10AD04 A10AD04 A10AD04 A10AD04 0
Insulin 17 A10AD05 A10AD05 A10AD05 A10AD05 0
Insulin 18 A10AD30 A10AD30 A10AD30 A10AD30 0
Insulin 19 A10AE01 A10AE01 A10AE01 A10AE01 0
Insulin 20 A10AE02 A10AE02 A10AE02 A10AE02 0
Insulin 21 A10AE03 A10AE03 A10AE03 A10AE03 0
Insulin 22 A10AE04 A10AE04 A10AE04 A10AE04 0
Insulin 23 A10AE05 A10AE05 A10AE05 A10AE05 0
Insulin 24 A10AE30 A10AE30 A10AE30 A10AE30 0
Insulin 25 A10AF01 A10AF01 A10AF01 A10AF01 0
Metformin A10BA02 A10BA02 A10BA02 A10BA02 0
Glipizide A10BB07 A10BB07 A10BB07 A10BB07 0
Pioglitazone 3 A10BD05 A10BD05 A10BD05 A10BD05 0
Pioglitazone 2 A10BD06 A10BD06 A10BD06 A10BD06 0
Pioglitazone 4 A10BD09 A10BD09 A10BD09 A10BD09 0
Pioglitazone 5 A10BD12 n/a n/a n/a 0
Rosiglitazone A10BG02 A10BG02 A10BG02 A10BG02 0
Pioglitazone 1 A10BG03 A10BG03 A10BG03 A10BG03 0
Cyproheptadine 2 A15AA01 A15AA01 A15AA01 A15AA01 2
Cyproheptadine 3 A15AA51 A15AA51 A15AA51 A15AA51 2
Clopidogrel B01AC04 B01AC04 B01AC04 B01AC04 0
Dipyridamole 1 B01AC07 B01AC07 B01AC07 B01AC07 1
Dipyridamole 2 B01AC36 n/a n/a n/a 1
Digitoxin 1 C01AA04 C01AA04 C01AA04 C01AA04 1
Digoxin 1 C01AA05 C01AA05 C01AA05 C01AA05 1
Digitoxin 2 C01AA54 C01AA54 C01AA54 C01AA54 1
Digoxin 2 C01AA55 C01AA55 C01AA55 C01AA55 1
Disopyramide C01BA03 C01BA03 C01BA03 C01BA03 2
Nitroglycerin C01DA02 C01DA02 C01DA02 C01DA02 0
Isosorbidedinitrate 1 C01DA08 C01DA08 C01DA08 C01DA08 1
Isosorbidemononitrate C01DA14 C01DA14 C01DA14 C01DA14 1
Isosorbidedinitrate 2 C01DA58 C01DA58 C01DA58 C01DA58 1
Dipyridamole 4 C01DX21 C01DX21 C01DX21 C01DX21 1
Dipyridamole 3 C01DX71 C01DX71 C01DX71 C01DX71 1
Theophylline 2 C01EB22 C01EB22 C01EB22 C01EB22 1
Theophylline 3 C01EX66 C01EX66 C01EX66 C01EX66 1
Hydralazine 1 C02DB02 C02DB02 C02DB02 C02DB02 1
Hydralazine 2 C02LG02 C02LG02 C02LG02 C02LG02 1
Hydrochlorothiazide C03AA03 C03AA03 C03AA03 C03AA03 0
Chlortalidone 1 C03BA04 C03BA04 C03BA04 C03BA04 1
Chlortalidone 2 C03BB04 C03BB04 C03BB04 C03BB04 1
Furosemide 1 C03CA01 C03CA01 C03CA01 C03CA01 1
Furosemide 2 C03CB01 C03CB01 C03CB01 C03CB01 1
Spironolactone C03DA01 C03DA01 C03DA01 C03DA01 0
Triamterene 1 C03DB02 C03DB02 C03DB02 C03DB02 1
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Chlortalidone 3 C03EA06 C03EA06 C03EA06 C03EA06 1
Triamterene 2 C03EA21 C03EA21 C03EA21 C03EA21 1
Furosemide 3 C03EB01 C03EB01 C03EB01 C03EB01 1
Furosemide 4 + Triamterene 
3
C03EB21 C03EB21 C03EB21 C03EB21 1
Isosorbidedinitrate 3 C05AE02 C05AE02 C05AE02 C05AE02 1
Digitoxin 3 C05BZ05 C05BZ05 C05BZ05 C05BZ05 1
Propranolol 1 C07AA05 C07AA05 C07AA05 C07AA05 0
Timolol C07AA06 C07AA06 C07AA06 C07AA06 0
Metoprolol 1 C07AB02 C07AB02 C07AB02 C07AB02 0
Atenolol 1 C07AB03 C07AB03 C07AB03 C07AB03 0
Atenolol 8 (Enantiomer S-
Atenolol)
C07AB11 C07AB11 C07AB11 C07AB11 0
Metoprolol 2 C07AB52 C07AB52 C07AB52 C07AB52 0
Propranolol 5 C07BA05 C07BA05 C07BA05 C07BA05 0
Metoprolol 3 C07BB02 C07BB02 C07BB02 C07BB02 0
Atenolol 2 C07BB03 C07BB03 C07BB03 C07BB03 0
Metoprolol 4 C07BB52 C07BB52 C07BB52 C07BB52 0
Propranolol 4 C07CA05 C07CA05 C07CA05 C07CA05 0
Metoprolol 5 C07CB02 C07CB02 C07CB02 C07CB02 0
Atenolol 3 C07CB03 C07CB03 C07CB03 C07CB03 0
Atenolol 4 C07CB53 C07CB53 C07CB53 C07CB53 0
Propranolol 2 C07DA05 C07DA05 C07DA05 C07DA05 0
Atenolol 5 C07DB01 C07DB01 C07DB01 C07DB01 0
Propranolol 6 C07EA05 C07EA05 C07EA05 C07EA05 0
Propranolol 3 C07FA05 C07FA05 C07FA05 C07FA05 0
Metoprolol 6 C07FB02 C07FB02 C07FB02 C07FB02 0
Atenolol 7 C07FB03 C07FB03 C07FB03 C07FB03 0
Metoprolol 7 C07FB22 C07FB22 C07FB22 C07FB22 0
Atenolol 6 C07FB23 C07FB23 C07FB23 C07FB23 0
Metoprolol 8 C07FB24 C07FB24 C07FB24 C07FB24 0
Amlodipine C08CA01 C08CA01 C08CA01 C08CA01 0
Verapamil 1 C08DA01 C08DA01 C08DA01 C08DA01 0
Verapamil 5 C08DA51 C08DA51 C08DA51 C08DA51 0
Verapamil 2 C08DA81 C08DA81 C08DA81 C08DA81 0
Diltiazem C08DB01 C08DB01 C08DB01 C08DB01 1
Verapamil 3 C08GA02 C08GA02 C08GA02 C08GA02 0
Captopril 1 C09AA01 C09AA01 C09AA01 C09AA01 1
Enalapril C09AA02 C09AA02 C09AA02 C09AA02 0
Lisinopril C09AA03 C09AA03 C09AA03 C09AA03 0
Benazepril C09AA07 C09AA07 C09AA07 C09AA07 0
Trandolapril C09AA10 C09AA10 C09AA10 C09AA10 0
Captopril 2 C09BA01 C09BA01 C09BA01 C09BA01 1
Verapamil 4 C09BB10 C09BB10 C09BB10 C09BB10 0
Losartan C09CA01 C09CA01 C09CA01 C09CA01 0
Simvastatin C10AA01 C10AA01 C10AA01 C10AA01 0
Atorvastatin C10AA05 C10AA05 C10AA05 C10AA05 0
Gemfibrozil C10AB04 C10AB04 C10AB04 C10AB04 0
Bromocriptine 2 G02CB01 G02CB01 G02CB01 G02CB01 1
Flavoxate G04BD02 G04BD02 G04BD02 G04BD02 3
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Oxybutynin G04BD04 G04BD04 G04BD04 G04BD04 3
Tolterodine G04BD07 G04BD07 G04BD07 G04BD07 3
Darifenacin G04BD10 G04BD10 G04BD10 G04BD10 3
Dicyclomine (=Dicycloverin) 2 G04BD13 G04BD13 G04BD13 G04BD13 3
Atropine 2 G04BD15 G04BD15 G04BD15 G04BD15 3
Dicyclomine (=Dicycloverin) 3 G04BD63 G04BD63 G04BD63 G04BD63 3
Atropine 3 G04BD65 G04BD65 G04BD65 G04BD65 3
Dexamethasone 1 H02AB02 H02AB02 H02AB02 H02AB02 1
Methylprednisolone 1 H02AB04 H02AB04 H02AB04 H02AB04 1
Prednisolone 1 H02AB06 H02AB06 H02AB06 H02AB06 1
Prednisolone 4 (Prednisone) H02AB07 H02AB07 H02AB07 H02AB07 1
Triamcinolone 1 H02AB08 H02AB08 H02AB08 H02AB08 1
Hydrocortisone 1 H02AB09 H02AB09 H02AB09 H02AB09 1
Cortisone H02AB10 H02AB10 H02AB10 H02AB10 1
Methylprednisolone 2 H02AB54 H02AB54 H02AB54 H02AB54 1
Prednisolone 2 H02AB56 H02AB56 H02AB56 H02AB56 1
Methylprednisolone 3 H02BX01 H02BX01 H02BX01 H02BX01 1
Dexamethasone 3 H02BX02 H02BX02 H02BX02 H02BX02 1
Prednisolone 3 H02BX06 H02BX06 H02BX06 H02BX06 1
Triamcinolone 2 H02BX08 H02BX08 H02BX08 H02BX08 1
Ampicillin 1 J01CA01 J01CA01 J01CA01 J01CA01 1
Ampicillin 5 (Prodrug 
Pivampicillin)
J01CA02 J01CA02 J01CA02 J01CA02 1
Amoxicillin J01CA04 J01CA04 J01CA04 J01CA04 0
Ampicillin 6 (Prodrug 
Bacampicilin)
J01CA06 J01CA06 J01CA06 J01CA06 1
Piperacillin 1 J01CA12 J01CA12 J01CA12 J01CA12 1
Ampicillin 7 (Prodrug 
Metampicillin)
J01CA14 J01CA14 J01CA14 J01CA14 1
Ampicillin 8 (Prodrug 
Talampicillin)
J01CA15 J01CA15 J01CA15 J01CA15 1
Ampicillin 2 J01CA51 J01CA51 J01CA51 J01CA51 1
Ampicillin 3 J01CR01 J01CR01 J01CR01 J01CR01 1
Piperacillin 2 J01CR05 J01CR05 J01CR05 J01CR05 1
Cefalexin J01DB01 J01DB01 J01DB01 J01DB01 0
Cefalotin J01DB03 J01DB03 J01DB03 J01DB03 1
Cefoxitin J01DC01 J01DC01 J01DC01 J01DC01 1
Cefamandole J01DC03 J01DC03 J01DC03 J01DC03 1
Trimethoprim J01EA01 J01EA01 J01EA01 J01EA01 0
Clindamycin J01FF01 J01FF01 J01FF01 J01FF01 1
Gentamicin 1 J01GB03 J01GB03 J01GB03 J01GB03 1
Gentamicin 2 J01GB53 J01GB53 J01GB53 J01GB53 1
Levofloxacin J01MA12 J01MA12 J01MA12 J01MA12 0
Vancomycin 1 J01XA01 J01XA01 J01XA01 J01XA01 1
Cycloserine J04AB01 J04AB01 J04AB01 J04AB01 1
Amantadine 2 J05AC04 J05AC04 J05AC04 J05AC04 1
Celecoxib 2 L01XX33 L01XX33 L01XX33 L01XX33 0
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Tamoxifen L02BA01 L02BA01 L02BA01 L02BA01 0
Ciclosporine L04AD01 L04AD01 L04AD01 L04AD01 1
Azathioprine L04AX01 L04AX01 L04AX01 L04AX01 1
Methotrexate L04AX03 L04AX03 L04AX03 L04AX03 0
Piroxicam 1 M01AC01 M01AC01 M01AC01 M01AC01 0
Ibuprofen M01AE01 M01AE01 M01AE01 M01AE01 0
Ketoprofen 1 M01AE03 M01AE03 M01AE03 M01AE03 0
Ketoprofen 2 M01AE53 M01AE53 M01AE53 M01AE53 0
Celecoxib 1 M01AH01 M01AH01 M01AH01 M01AH01 0
Piroxicam 2 M02AA07 M02AA07 M02AA07 M02AA07 0
Ketoprofen 3 M02AA10 M02AA10 M02AA10 M02AA10 0
Pancuronium M03AC01 M03AC01 M03AC01 M03AC01 1
Carisoprodol 1 M03BA02 M03BA02 M03BA02 M03BA02 0
Carisoprodol 2 M03BA52 M03BA52 M03BA52 M03BA52 0
Carisoprodol 3 M03BA72 M03BA72 M03BA72 M03BA72 0
Orphenadrine 1 M03BC01 M03BC01 M03BC01 M03BC01 3
Orphenadrine 2 M03BC51 M03BC51 M03BC51 M03BC51 3
Baclofen M03BX01 M03BX01 M03BX01 M03BX01 0
Cyclobenzaprine M03BX08 M03BX08 M03BX08 M03BX08 2
Allopurinol M04AA01 M04AA01 M04AA01 M04AA01 0
Colchicine M04AC01 M04AC01 M04AC01 M04AC01 0
Fentanyl 2 N01AH01 N01AH01 N01AH01 N01AH01 1
Fentanyl 3 N01AH51 N01AH51 N01AH51 N01AH51 1
Diphenhydramine 4 N01BX06 N01BX06 N01BX06 N01BX06 3
Morphine 1 N02AA01 N02AA01 N02AA01 N02AA01 1
Oxycodone 1 N02AA05 N02AA05 N02AA05 N02AA05 1
Codeine 10 (Dihydrocodeine 
1)
N02AA08 N02AA08 N02AA08 N02AA08 1
Morphine 3 N02AA51 N02AA51 N02AA51 N02AA51 1
Oxycodone 2 N02AA55 N02AA55 N02AA55 N02AA55 1
Codeine 11 (Dihydrocodeine 
2)
N02AA58 N02AA58 N02AA58 N02AA58 1
Codeine 2 N02AA59 N02AA59 N02AA59 N02AA59 1
Codeine 3 N02AA64 N02AA64 N02AA64 N02AA64 1
Codeine 4 N02AA65 N02AA65 N02AA65 N02AA65 1
Codeine 5 N02AA66 N02AA66 N02AA66 N02AA66 1
Codeine 6 N02AA69 N02AA69 N02AA69 N02AA69 1
Codeine 7 N02AA79 N02AA79 N02AA79 N02AA79 1
Pethidine (=Meperidine) 1 N02AB02 N02AB02 N02AB02 N02AB02 2
Fentanyl 1 N02AB03 N02AB03 N02AB03 N02AB03 1
Pethidine (=Meperidine) 2
N02AB52 N02AB52 N02AB52 N02AB52
2
Pethidine (=Meperidine) 3
N02AB72 N02AB72 N02AB72 N02AB72
2
Morphine 4 N02AG01 N02AG01 N02AG01 N02AG01 1
Pethidine (=Meperidine) 4
N02AG03 N02AG03 N02AG03 N02AG03
2
Tramadol 1 N02AX02 N02AX02 N02AX02 N02AX02 1
Tramadol 2 N02AX52 N02AX52 N02AX52 N02AX52 1
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Acetylsalicylicacid N02BA01 N02BA01 N02BA01 N02BA01 0
Paracetamol N02BE01 N02BE01 N02BE01 N02BE01 0
Topiramate 2 N02CX12 N02CX12 N02CX12 N02CX12 0
Codeine 8 N02CX58 N02CX58 N02CX58 N02CX58 1
Metoclopramide 3 N02CX59 N02CX59 N02CX59 N02CX59 0
Phenobarbital 1 N03AA02 N03AA02 N03AA02 N03AA02 0
Phenytoin 1 N03AB02 N03AB02 N03AB02 N03AB02 0
Phenytoin 3 (Fosphenytoin) N03AB05 N03AB05 N03AB05 N03AB05 0
Phenytoin 2 N03AB52 N03AB52 N03AB52 N03AB52 0
Clonazepam N03AE01 N03AE01 N03AE01 N03AE01 1
Midazolam 2 N03AE02 N03AE02 n/a n/a 1
Carbamazepine N03AF01 N03AF01 N03AF01 N03AF01 2
Oxcarbazepine N03AF02 N03AF02 N03AF02 N03AF02 2
Valproic acid / Sodium 
Valproate
N03AG01 N03AG01 N03AG01 N03AG01 1
Topiramate 1 N03AX11 N03AX11 N03AX11 N03AX11 0
Trihexyphenidyl N04AA01 N04AA01 N04AA01 N04AA01 3
Procyclidine N04AA04 N04AA04 N04AA04 N04AA04 3
Orphenadrine 3 N04AB02 N04AB02 N04AB02 N04AB02 3
Benzatropine 1 N04AC01 N04AC01 N04AC01 N04AC01 3
Benzatropine 2 
(Etybenzatropin)
N04AC30 N04AC30 N04AC30 N04AC30 3
Levodopa 1 N04BA01 N04BA01 N04BA01 N04BA01 0
Entacapone 2 + Levodopa 3 N04BA03 N04BA03 N04BA03 N04BA03 0
Levodopa 6 (Melevodopa 1) N04BA04 N04BA04 N04BA04 N04BA04 0
Levodopa 7 (Melevodopa 2) N04BA05 N04BA05 N04BA05 N04BA05 0
Levodopa 5 (Etilevodopa) N04BA06 N04BA06 N04BA06 N04BA06 0
Levodopa 2 N04BA10 N04BA10 N04BA10 N04BA10 0
Levodopa 4 N04BA11 N04BA11 N04BA11 N04BA11 0
Amantadine 1 N04BB01 N04BB01 N04BB01 N04BB01 1
Bromocriptine 1 N04BC01 N04BC01 N04BC01 N04BC01 1
Ropinirole N04BC04 N04BC04 N04BC04 N04BC04 0
Pramipexol N04BC05 N04BC05 N04BC05 N04BC05 0
Selegiline N04BD01 N04BD01 N04BD01 N04BD01 0
Entacapone 1 N04BX02 N04BX02 N04BX02 N04BX02 0
Chlorpromazine N05AA01 N05AA01 N05AA01 N05AA01 3
Levomepromazine N05AA02 N05AA02 N05AA02 N05AA02 2
Fluphenazine N05AB02 N05AB02 N05AB02 N05AB02 1
Perphenazine N05AB03 N05AB03 N05AB03 N05AB03 1
Prochlorperazine N05AB04 N05AB04 N05AB04 N05AB04 1
Trifluoperazine N05AB06 N05AB06 N05AB06 N05AB06 1
Thioridazine N05AC02 N05AC02 N05AC02 N05AC02 3
Haloperidol N05AD01 N05AD01 N05AD01 N05AD01 0
Molindone N05AE02 N05AE02 N05AE02 N05AE02 2
Tiotixene N05AF04 N05AF04 N05AF04 N05AF04 1
Pimozide N05AG02 N05AG02 N05AG02 N05AG02 2
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Loxapine N05AH01 N05AH01 N05AH01 N05AH01 2
Clozapine N05AH02 N05AH02 N05AH02 N05AH02 3
Olanzapine N05AH03 N05AH03 N05AH03 N05AH03 1
Quetiapine  (fumarate) N05AH04 N05AH04 N05AH04 N05AH04 0
Lithium N05AN01 N05AN01 N05AN01 N05AN01 0
Diazepam N05BA01 N05BA01 N05BA01 N05BA01 1
Chlordiazepoxide N05BA02 N05BA02 N05BA02 N05BA02 1
Oxazepam N05BA04 N05BA04 N05BA04 N05BA04 1
Clorazepate N05BA05 N05BA05 N05BA05 N05BA05 1
Lorazepam 1 N05BA06 N05BA06 N05BA06 N05BA06 1
Alprazolam N05BA12 N05BA12 N05BA12 N05BA12 1
Lorazepam 2 N05BA56 N05BA56 N05BA56 N05BA56 1
Hydroxyzine 1 N05BB01 N05BB01 N05BB01 N05BB01 3
Hydroxyzine 3 N05BB51 N05BB51 N05BB51 N05BB51 3
Phenobarbital 2 N05CA24 N05CA24 N05CA24 N05CA24 0
Flurazepam N05CD01 N05CD01 N05CD01 N05CD01 1
Estazolam N05CD04 N05CD04 N05CD04 N05CD04 1
Triazolam N05CD05 N05CD05 N05CD05 N05CD05 1
Temazepam N05CD07 N05CD07 N05CD07 N05CD07 1
Midazolam 1 N05CD08 N05CD08 N05CD08 N05CD08 1
Zopiclone N05CF01 N05CF01 N05CF01 N05CF01 0
Zolpidem N05CF02 N05CF02 N05CF02 N05CF02 0
Scopolamine 3 (=Hyoscin) N05CM05 N05CM05 N05CM05 N05CM05 3
Diphenhydramine 5 N05CM20 N05CM20 N05CM20 N05CM20 3
Promethazine 4 N05CM22 N05CM22 N05CM22 N05CM22 3
Diphenhydramine 2 N05CX07 N05CX07 N05CX07 N05CX07 3
Promethazine 5 N05CX13 N05CX13 N05CX13 N05CX13 3
Desipramine N06AA01 N06AA01 N06AA01 N06AA01 3
Imipramine 1 N06AA02 N06AA02 N06AA02 N06AA02 3
Imipramine 2 N06AA03 N06AA03 N06AA03 N06AA03 3
Clomipramine N06AA04 N06AA04 N06AA04 N06AA04 3
Trimipramine N06AA06 N06AA06 N06AA06 N06AA06 3
Amitriptyline 1 N06AA09 N06AA09 N06AA09 N06AA09 3
Nortriptyline 1 N06AA10 N06AA10 N06AA10 N06AA10 3
Protriptyline N06AA11 N06AA11 N06AA11 N06AA11 3
Doxepin N06AA12 N06AA12 N06AA12 N06AA12 3
Amitriptyline 3 N06AA25 N06AA25 N06AA25 N06AA25 3
Fluoxetine 1 N06AB03 N06AB03 N06AB03 N06AB03 1
Citalopram N06AB04 N06AB04 N06AB04 N06AB04 0
Paroxetine N06AB05 N06AB05 N06AB05 N06AB05 1
Fluvoxamine N06AB08 N06AB08 N06AB08 N06AB08 1
Escitalopram N06AB10 N06AB10 N06AB10 N06AB10 0
Phenelzine N06AF03 N06AF03 N06AF03 N06AF03 1
Trazodone N06AX05 N06AX05 N06AX05 N06AX05 0
Nefazodone N06AX06 N06AX06 N06AX06 N06AX06 0
Mirtazapine N06AX11 N06AX11 N06AX11 N06AX11 0
Bupropion 1 N06AX12 N06AX12 N06AX12 N06AX12 0
Venlafaxine 1 N06AX16 N06AX16 N06AX16 N06AX16 0
Duloxetine N06AX21 N06AX21 N06AX21 N06AX21 0
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Venlafaxine 2 
(Desvenlafaxine)
N06AX23 N06AX23 N06AX23 N06AX23 0
Amitriptyline 2 N06CA01 N06CA01 N06CA01 N06CA01 3
Fluoxetine 2 N06CA03 n/a n/a n/a 1
Nortriptyline 2 N06CA06 N06CA06 N06CA06 N06CA06 3
Donepezil N06DA02 N06DA02 N06DA02 N06DA02 0
Galantamine N06DA04 N06DA04 N06DA04 N06DA04 0
Bupropion 2 N07BA02 N07BA02 N07BA02 N07BA02 0
Pseudoephedrine 1 R01BA02 R01BA02 R01BA02 R01BA02 0
Pseudoephedrine 2 R01BA52 R01BA52 R01BA52 R01BA52 0
Terbutaline (oral) 2 R03AC03 R03AC03 R03AC03 R03AC03 0
Fluticasone-salmeterol R03AK06 R03AK61 R03AK61 R03AK61 1
Ipratropium R03BB01 R03BB01 R03BB01 R03BB01 0
Terbutaline (oral) 1 R03CC03 R03CC03 R03CC03 R03CC03 0
Terbutaline (oral) 3 R03CC53 R03CC53 R03CC53 R03CC53 0
Theophylline 1 R03DA04 R03DA04 R03DA04 R03DA04 1
Theophylline 4 R03DA54 R03DA54 R03DA54 R03DA54 1
Theophylline 5 R03DA74 R03DA74 R03DA74 R03DA74 1
Theophylline 6 R03DB04 R03DB04 R03DB04 R03DB04 1
Guaifenesin R05CA03 R05CA03 R05CA03 R05CA03 0
Hydrocodone R05DA03 R05DA03 R05DA03 R05DA03 0
Codeine 1 R05DA04 R05DA04 R05DA04 R05DA04 1
Morphine 5 R05DA05 R05DA05 R05DA05 R05DA05 1
Codeine 12 (Dihydrocodeine 
3)
R05DA14 R05DA14 R05DA14 R05DA14 1
Codeine 9 R05DA54 R05DA54 R05DA54 R05DA54 1
Codeine 13 (Dihydrocodeine 
4)
R05DA64 R05DA64 R05DA64 R05DA64 1
Ampicillin 4 R05GB05 R05GB05 R05GB05 R05GB05 1
Diphenhydramine 1 R06AA02 R06AA02 R06AA02 R06AA02 3
Clemastine 1 R06AA04 R06AA04 R06AA04 R06AA04 3
Carbinoxamine R06AA08 R06AA08 R06AA08 R06AA08 3
Diphenhydramine 7 R06AA52 R06AA52 R06AA52 R06AA52 3
Clemastine 2 R06AA54 R06AA54 R06AA54 R06AA54 3
Brompheniramine 1 R06AB01 R06AB01 R06AB01 R06AB01 3
Chlorpheniramine 
(=Chlorphenamine) 1
R06AB04 R06AB04 R06AB04 R06AB04 3
Brompheniramine 2 R06AB51 R06AB51 R06AB51 R06AB51 3
Chlorpheniramine 
(=Chlorphenamine) 2 R06AB54 R06AB54 R06AB54 R06AB54
3
Pyrilamine R06AC01 R06AC01 R06AC01 R06AC01 3
Promethazine 1 R06AD02 R06AD02 R06AD02 R06AD02 3
Promethazine 8 
(Hydroxyethylpromethazin 1)
R06AD05 R06AD05 R06AD05 R06AD05
3
Promethazine 7 
(Dioxopromethazin)
R06AD10 R06AD10 R06AD10 R06AD10 3
Promethazine 2 R06AD52 R06AD52 R06AD52 R06AD52 3
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open
 doi: 10.1136/bmjopen-2020-039747:e039747. 10 2020;BMJ Open, et al. Müller BS
Promethazine 9 
(Hydroxyethylpromethazin 2)
R06AD55 R06AD55 R06AD55 R06AD55 3
Meclozine 1 R06AE05  R06AE05  R06AE05  R06AE05  3
Cetirizin 1 R06AE07 R06AE07 R06AE07 R06AE07 0
Cetirizin 3 (Enantiomer 
Levocetirizin )
R06AE09 R06AE09 R06AE09 R06AE09 0
Meclozine 2 R06AE55 R06AE55 R06AE55 R06AE55 3
Cetirizin 2 R06AE57 R06AE57 R06AE57 R06AE57 0
Cyproheptadine 1 R06AX02 R06AX02 R06AX02 R06AX02 2
Loratadine 1 R06AX13 R06AX13 R06AX13 R06AX13 0
Ketotifen R06AX17 R06AX17 R06AX17 R06AX17 1
Fexofenadine R06AX26 R06AX26 R06AX26 R06AX26 0
Loratadine 2 (Enantiomer 
Desloratadin )
R06AX27 R06AX27 R06AX27 R06AX27 0
Hydroxyzine 2 R06AX32 R06AX32 R06AX32 R06AX32 3
Promethazine 6 V03AB05 V03AB05 V03AB05 V03AB05 3
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open
 doi: 10.1136/bmjopen-2020-039747:e039747. 10 2020;BMJ Open, et al. Müller BS
Drug Burden Index 
Medication IDIS ingredient 
code (IDIS=Iowa Drug 
Information System)
Medication ATC-Code 
2014
ATC-Code 
2013
ATC-Code 
2012
ATC-Code 
2011
Dicyclomine 12080005 Dicycloverine A03AA07 A03AA07 A03AA07 A03AA07
Propantheline 12080008 Propantheline 1 A03AB05 A03AB05 A03AB05 A03AB05
Papaverine 86000007 Papaverine 1 A03AD01 A03AD01 A03AD01 A03AD01
Belladonna alkaloids 2 A03BA01 A03BA01 A03BA01 A03BA01
Hyoscyamine 12080079 Hyoscyamine 1 + Belladonna 
alkaloids 3
A03BA03 A03BA03 A03BA03 A03BA03
Belladonna alkaloids 4 A03BA04 A03BA04 A03BA04 A03BA04
Belladonna alkaloids 5 A03BA20 A03BA20 A03BA20 A03BA20
Belladonna alkaloids 6 A03BB01 A03BB01 A03BB01 A03BB01
Belladonna alkaloids 7 A03BB02 A03BB02 A03BB02 A03BB02
Methscopolamine 
12080007
Methscopolamine 1 
(Belladonna alkaloids 8)
A03BB03 A03BB03 A03BB03 A03BB03
Belladonna alkaloids 9 A03BB04 A03BB04 A03BB04 A03BB04
Belladonna alkaloids 10 A03BB05 A03BB05 A03BB05 A03BB05
Clidinium 12080047 Clidinium A03CA02 A03CA02 A03CA02 A03CA02
Propantheline 2 A03CA34 A03CA34 A03CA34 A03CA34 
Methscopolamine 2 
(Belladonna alkaloids 11)
A03CB01 A03CB01 A03CB01 A03CB01 
Belladonna alkaloids 12 A03CB02 A03CB02 A03CB02 A03CB02
Belladonna alkaloids 13 A03CB03 A03CB03 A03CB03 A03CB03
Belladonna alkaloids 14 A03CB04 A03CB04 A03CB04 A03CB04
Hyoscyamine 2 (Belladonna 
alkaloids 15) A03CB31 A03CB31 A03CB31 A03CB31
Belladonna alkaloids 16 A03CB37 A03CB37 A03CB37 A03CB37
Belladonna alkaloids 17 A03CB38 A03CB38 A03CB38 A03CB38
Belladonna alkaloids 18 A03DB04 A03DB04 A03DB04 A03DB04
Metoclopramide 56220098 Metoclopramide 1 A03FA01 A03FA01 A03FA01 A03FA01
Metoclopramide 2 A03FA51 A03FA51 A03FA51 A03FA51
Dimenhydrinate 56220003 Dimenhydrinate 1 A04AB02 A04AB02 A04AB02 A04AB02
Meclozine 3 A04AB04 A04AB04 A04AB04 A04AB04
Diphenhydramine 3 A04AB05 A04AB05 A04AB05 A04AB05
Dimenhydrinate 2 A04AB52 A04AB52 A04AB52 A04AB52
Meclozine 4 A04AB54 A04AB54 A04AB54 A04AB54
Diphenhydramine 6 A04AB55 A04AB55 A04AB55 A04AB55
Doxylamine 4 A04AB56 A04AB56 A04AB56 A04AB56
Promethazine 3 A04AB58 A04AB58 A04AB58 A04AB58
Triflupromazine 2 A04AD06 A04AD06 A04AD06 A04AD06
Belladonna 12080002 Belladonna alkaloids 1 A06AB30 A06AB30 A06AB30 A06AB30
Diphenoxylate 56080005 Diphenoxylate A07DA01 A07DA01 A07DA01 A07DA01
Opium 28080881 Opium 1 A07DA02 A07DA02 A07DA02 A07DA02
Loperamide 56080009 Loperamide 1 A07DA03 A07DA03 A07DA03 A07DA03
Morphine 2 A07DA52 A07DA52 A07DA52 A07DA52
Loperamide 2 A07DA53 A07DA53 A07DA53 A07DA53
Cyproheptadine 2 A15AA01 A15AA01 A15AA01 A15AA01
Cyproheptadine 3 A15AA51 A15AA51 A15AA51 A15AA51
Disopyramide 24040024 Disopyramide C01BA03 C01BA03 C01BA03 C01BA03
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Reserpine 24080010 Reserpine 1 C02AA02 C02AA02 C02AA02 C02AA02
Reserpine 2 C02AA52 C02AA52 C02AA52 C02AA52
Methyldopa 24080006 Methyldopa 1 C02AB01 C02AB01 C02AB01 C02AB01
Methyldopa 2 C02AB02 C02AB02 C02AB02 C02AB02
Clonidine 24080064 Clonidine 1 C02AC01 C02AC01 C02AC01 C02AC01
Guanfacine 24080063 Guanfacine C02AC02 C02AC02 C02AC02 C02AC02
Prazosin 12160404 Prazosin 1 C02CA01 C02CA01 C02CA01 C02CA01
Doxazosin 12160419 Doxazosin 1 C02CA04 C02CA04 C02CA04 C02CA04
Terazosin 2 C02CA08 C02CA08 C02CA08 C02CA08
Guanethidine 24080003 Guanethidine 1 C02CC02 C02CC02 C02CC02 C02CC02
Guanabenz 24080084 Guanoxabenz C02CC07 C02CC07 C02CC07 C02CC07
Reserpine 3 C02LA01 C02LA01 C02LA01 C02LA01
Reserpine 4 C02LA51 C02LA51 C02LA51 C02LA51
Reserpine 5 C02LA71 C02LA71 C02LA71 C02LA71
Methyldopa 3 C02LB01 C02LB01 C02LB01 C02LB01
Clonidine 2 C02LC01 C02LC01 C02LC01 C02LC01
Clonidine 3 C02LC51 C02LC51 C02LC51 C02LC51
Prazosin 2 C02LE01 C02LE01 C02LE01 C02LE01
Guanethidine 2 C02LF01 C02LF01 C02LF01 C02LF01
Flavoxate 12080039 Flavoxate G04BD02 G04BD02 G04BD02 G04BD02
Oxybutynin 86000004 Oxybutynin G04BD04 G04BD04 G04BD04 G04BD04
Tolterodine 86000047 Tolterodine G04BD07 G04BD07 G04BD07 G04BD07
Papaverine 2 G04BE02 G04BE02 G04BE02 G04BE02
Tamulosin 12160411 Tamsulosin 1 G04CA02 G04CA02 G04CA02 G04CA02
Terazosin 12160401 Terazosin 1 G04CA03 G04CA03 G04CA03 G04CA03
Doxazosin 2 G04CA05 G04CA05 G04CA05 G04CA05
Tamsulosin 2 G04CA52 G04CA52 G04CA52 G04CA52
Tamsulosin 3 G04CA53 G04CA53 G04CA53 G04CA53
Carisoprodol 12200001 Carisoprodol 1 M03BA02 M03BA02 M03BA02 M03BA02
Methocarbamol 12200005 Methocarbamol 1 M03BA03 M03BA03 M03BA03 M03BA03
Carisoprodol 2 M03BA52 M03BA52 M03BA52 M03BA52
Methocarbamol 2 M03BA53 M03BA53 M03BA53 M03BA53
Meprobamate 4 M03BA57 M03BA57 M03BA57 M03BA57
Carisoprodol 3 M03BA72 M03BA72 M03BA72 M03BA72
Methocarbamol 3 M03BA73 M03BA73 M03BA73 M03BA73
Chlorzoxazone 12200091 Chlorzoxazone 1 M03BB03 M03BB03 M03BB03 M03BB03
Chlorzoxazone 3 M03BB53 M03BB53 M03BB53 M03BB53
Chlorzoxazone 2 M03BB73 M03BB73 M03BB73 M03BB73
Orphenadrine 12080804 Orphenadrine 1 M03BC01 M03BC01 M03BC01 M03BC01
Orphenadrine 2 M03BC51 M03BC51 M03BC51 M03BC51
Cyclobenzaprine 12200009 Cyclobenzaprine M03BX08 M03BX08 M03BX08 M03BX08
Hexobarbital 28240405 Hexobarbital 1 N01AF02 N01AF02 N01AF02 N01AF02
Fentanyl 2 N01AH01 N01AH01 N01AH01 N01AH01
Fentanyl 3 N01AH51 N01AH51 N01AH51 N01AH51
Diphenhydramine 4 N01BX06 N01BX06 N01BX06 N01BX06
Morphine 28080819 Morphine 1 N02AA01 N02AA01 N02AA01 N02AA01
Opium 2 N02AA02 N02AA02 N02AA02 N02AA02
Oxycodone 28080883 Oxycodone 1 N02AA05 N02AA05 N02AA05 N02AA05
Codeine 10 (Dihydrocodeine 
1)
N02AA08 N02AA08 N02AA08 N02AA08
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Morphine 3 N02AA51 N02AA51 N02AA51 N02AA51
Oxycodone 2 N02AA55 N02AA55 N02AA55 N02AA55
Codeine 11 (Dihydrocodeine 
2)
N02AA58 N02AA58 N02AA58 N02AA58
Codeine 2 N02AA59 N02AA59 N02AA59 N02AA59
Codeine 3 N02AA64 N02AA64 N02AA64 N02AA64
Codeine 4 N02AA65 N02AA65 N02AA65 N02AA65
Codeine 5 N02AA66 N02AA66 N02AA66 N02AA66
Codeine 6 N02AA69 N02AA69 N02AA69 N02AA69
Codeine 7 N02AA79 N02AA79 N02AA79 N02AA79
Fentanyl 28080810 Fentanyl 1 N02AB03 N02AB03 N02AB03 N02AB03
Propoxyphene 28080840 Propoxyphene N02AC04 N02AC04 N02AC04 N02AC04
Methadone 3 
(Levomethadone)
N02AC06 N02AC06 N02AC06 N02AC06
Methadone 2 N02AC52 N02AC52 N02AC52 N02AC52
Pentazocine 28080892 Pentazocine N02AD01 N02AD01 N02AD01 N02AD01
Morphine 4 N02AG01 N02AG01 N02AG01 N02AG01
Tramadol 28080854 Tramadol 1 N02AX02 N02AX02 N02AX02 N02AX02
Tramadol 2 N02AX52 N02AX52 N02AX52 N02AX52
Clonidine 4 N02CX02 N02CX02 N02CX02 N02CX02
Codeine 8 N02CX58 N02CX58 N02CX58 N02CX58
Metoclopramide 3 N02CX59 N02CX59 N02CX59 N02CX59
Phenobarbital 28120405 Phenobarbital 1 N03AA02 N03AA02 N03AA02 N03AA02
Primidone 28120407 Primidone N03AA03 N03AA03 N03AA03 N03AA03
Phenytoin 28120805 Phenytoin 1 N03AB02 N03AB02 N03AB02 N03AB02
Phenytoin 3 (Fosphenytoin) N03AB05 N03AB05 N03AB05 N03AB05
Phenytoin 2 N03AB52 N03AB52 N03AB52 N03AB52
Clonazepam 28240212 Clonazepam N03AE01 N03AE01 N03AE01 N03AE01
Carbamazepine 28122007 Carbamazepine N03AF01 N03AF01 N03AF01 N03AF01
Oxcarbazepine 28122011 Oxcarbazepine N03AF02 N03AF02 N03AF02 N03AF02
Valproic acid 28122015 Valproic acid / Sodium 
Valproate
N03AG01 N03AG01 N03AG01 N03AG01
Tiagabine 28122034 Tiagabine N03AG06 N03AG06 N03AG06 N03AG06
Lamotrigine 28122024 Lamotrigine N03AX09 N03AX09 N03AX09 N03AX09
Gabapentin 28122020 Gabapentin N03AX12 N03AX12 N03AX12 N03AX12
Levetiracetam 28122040 Levetiracetam N03AX14 N03AX14 N03AX14 N03AX14
Trihexyphenidyl 12080802 Trihexyphenidyl N04AA01 N04AA01 N04AA01 N04AA01
Orphenadrine 3 N04AB02 N04AB02 N04AB02 N04AB02
Benztropine 12080806 Benzatropine 1 N04AC01 N04AC01 N04AC01 N04AC01
Benzatropine 2 
(Etybenzatropin)
N04AC30 N04AC30 N04AC30 N04AC30
Ropinerole 28280011 Ropinerole N04BC04 N04BC04 N04BC04 N04BC04
Pramipexole 28280013 Pramipexole N04BC05 N04BC05 N04BC05 N04BC05
Selegiline 28160520 Selegiline N04BD01 N04BD01 N04BD01 N04BD01
Chlorpromazine 56220089 Chlorpromazine N05AA01 N05AA01 N05AA01 N05AA01
Triflupromazine 28160996 Triflupromazine 1 N05AA05 N05AA05 N05AA05 N05AA05
Fluphenazine 28160906 Fluphenazine N05AB02 N05AB02 N05AB02 N05AB02
Perphenazine 28160909 Perphenazine N05AB03 N05AB03 N05AB03 N05AB03
Prochlorperazine 56220096 Prochlorperazine N05AB04 N05AB04 N05AB04 N05AB04
Trifluoperazine 28160913 Trifluoperazine N05AB06 N05AB06 N05AB06 N05AB06
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Thioridazine 28160912 Thioridazine N05AC02 N05AC02 N05AC02 N05AC02
Haloperidol 28161014 Haloperidol N05AD01 N05AD01 N05AD01 N05AD01
Ziprasidone 28160844 Ziprasidone N05AE04 N05AE04 N05AE04 N05AE04
Chlorprothixine 28160804 Chlorprothixene N05AF03 N05AF03 N05AF03 N05AF03
Loxapine 28160858 Loxapine N05AH01 N05AH01 N05AH01 N05AH01
Olanzapine 28160836 Olanzapine N05AH03 N05AH03 N05AH03 N05AH03
Quetiapine 28160834 Quetiapine N05AH04 N05AH04 N05AH04 N05AH04
Risperidone 28160822 Risperidone N05AX08 N05AX08 N05AX08 N05AX08
Reserpine 6 N05AX15 N05AX15 N05AX15 N05AX15
Diazepam 28240205 Diazepam N05BA01 N05BA01 N05BA01 N05BA01
Chlordiazepoxide 28240202 Chlordiazepoxide N05BA02 N05BA02 N05BA02 N05BA02
Oxazepam 28240215 Oxazepam N05BA04 N05BA04 N05BA04 N05BA04
Clorazepate 28240228 Clorazepate N05BA05 N05BA05 N05BA05 N05BA05
Lorazepam 28240276 Lorazepam 1 N05BA06 N05BA06 N05BA06 N05BA06
Alprazolam 28240232 Alprazolam N05BA12 N05BA12 N05BA12 N05BA12
Lorazepam 2 N05BA56 N05BA56 N05BA56 N05BA56
Hydroxyzine 28160807 Hydroxyzine 1 N05BB01 N05BB01 N05BB01 N05BB01
Hydroxyzine 3 N05BB51 N05BB51 N05BB51 N05BB51
Meprobamate 28240820 Meprobamate 1 N05BC01 N05BC01 N05BC01 N05BC01
Meprobamate 2 N05BC51 N05BC51 N05BC51 N05BC51
Buspirone 28240837 Buspirone N05BE01 N05BE01 N05BE01 N05BE01
Hexobarbital 2 N05CA16 N05CA16 N05CA16 N05CA16
Phenobarbital 2 N05CA24 N05CA24 N05CA24 N05CA24
Dichloralphenazone 
28240828
Dichloralphenazone N05CC04 N05CC04 N05CC04 N05CC04
Flurazepam 28240206 Flurazepam N05CD01 N05CD01 N05CD01 N05CD01
Estazolam 28240216 Estazolam N05CD04 N05CD04 N05CD04 N05CD04
Triazolam 28240222 Triazolam N05CD05 N05CD05 N05CD05 N05CD05
Temazepam 28240231 Temazepam N05CD07 N05CD07 N05CD07 N05CD07
Zolpidem 28240834 Zolpidem N05CF02 N05CF02 N05CF02 N05CF02
Zaleplon 28240856 Zaleplon N05CF03 N05CF03 N05CF03 N05CF03
Diphenhydramine 5 N05CM20 N05CM20 N05CM20 N05CM20
Doxylamine 3 N05CM21 N05CM21 N05CM21 N05CM21
Promethazine 4 N05CM22 N05CM22 N05CM22 N05CM22
Meprobamate 3 N05CX01 N05CX01 N05CX01 N05CX01
Diphenhydramine 2 N05CX07 N05CX07 N05CX07 N05CX07
Promethazine 5 N05CX13 N05CX13 N05CX13 N05CX13
Desipramine 28160689 Desipramine N06AA01 N06AA01 N06AA01 N06AA01
Imipramine 28160602 Imipramine 1 N06AA02 N06AA02 N06AA02 N06AA02
Imipramine 2 N06AA03 N06AA03 N06AA03 N06AA03
Clomipramine 28160688 Clomipramine N06AA04 N06AA04 N06AA04 N06AA04
Trimipramine 28160650 Trimipramine N06AA06 N06AA06 N06AA06 N06AA06
Amitriptyline 28160601 Amitriptyline 1 N06AA09 N06AA09 N06AA09 N06AA09
Nortryptyline 28160695 Nortriptyline 1 N06AA10 N06AA10 N06AA10 N06AA10
Doxepin 28160681 Doxepin N06AA12 N06AA12 N06AA12 N06AA12
Amitriptyline 3 N06AA25 N06AA25 N06AA25 N06AA25
Fluoxetine 28160701 Fluoxetine 1 N06AB03 N06AB03 N06AB03 N06AB03
Citalopram 28160705 Citalopram N06AB04 N06AB04 N06AB04 N06AB04
Paroxetine 28160702 Paroxetine N06AB05 N06AB05 N06AB05 N06AB05
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Sertraline 28160703 Sertraline N06AB06 N06AB06 N06AB06 N06AB06
Ecitalopram 28160711 Escitalopram N06AB10 N06AB10 N06AB10 N06AB10
Phenelzine 28160505 Phenelzine N06AF03 N06AF03 N06AF03 N06AF03
Tranylcypromine 28160601 Tranylcypromine 1 N06AF04 N06AF04 N06AF04 N06AF04
Trazodone 28160415 Trazodone N06AX05 N06AX05 N06AX05 N06AX05
Nefazodone 28160486 Nefazodone N06AX06 N06AX06 N06AX06 N06AX06
Mirtazepine 28160617 Mirtazapine N06AX11 N06AX11 N06AX11 N06AX11
Venlafaxine 28160458 Venlafaxine 1 N06AX16 N06AX16 N06AX16 N06AX16
Venlafaxine 2 
(Desvenlafaxine)
N06AX23 N06AX23 N06AX23 N06AX23
Amitriptyline 2 N06CA01 N06CA01 N06CA01 N06CA01
Fluoxetine 2 N06CA03 n/a n/a n/a
Nortriptyline 2 N06CA06 N06CA06 N06CA06 N06CA06
Tranylcypromine 2 N06CA07 N06CA03 N06CA03 N06CA03
Clonidine 5 N07BB06 N07BB06 N07BB06 N07BB06
Methadone 28080818 Methadone 1 N07BC02 N07BC02 N07BC02 N07BC02
Dextrometorphan 2 N07XX59 n/a n/a n/a
Hydrocodone 48000072 Hydrocodone R05DA03 R05DA03 R05DA03 R05DA03
Codeine 48000063 Codeine 1 R05DA04 R05DA04 R05DA04 R05DA04
Morphine 5 R05DA05 R05DA05 R05DA05 R05DA05
Dextromethorphan 
48000069
Dextrometorphan 1 R05DA09 R05DA09 R05DA09 R05DA09
Codeine 12 (Dihydrocodeine 
3)
R05DA14 R05DA14 R05DA14 R05DA14
Codeine 9 R05DA54 R05DA54 R05DA54 R05DA54
Dextrometorphan 3 R05DA59 R05DA59 R05DA59 R05DA59
Codeine 13 (Dihydrocodeine 
4)
R05DA64 R05DA64 R05DA64 R05DA64
Benzonatate 48000054 Benzonatate R05DB01 R05DB01 R05DB01 R05DB01
Diphenhydramine 4000006 Diphenhydramine 1 R06AA02 R06AA02 R06AA02 R06AA02
Clemastine 4000054 Clemastine 1 R06AA04 R06AA04 R06AA04 R06AA04
Doxylamine 4000068 Doxylamine 1 R06AA09 R06AA09 R06AA09 R06AA09
Trimethobenzamide 
56220006
Trimethobenzamide R06AA10 R06AA10 R06AA10 R06AA10
Diphenhydramine 7 R06AA52 R06AA52 R06AA52 R06AA52
Clemastine 2 R06AA54 R06AA54 R06AA54 R06AA54
Doxylamine 2 R06AA59 R06AA59 n/a n/a
Brompheniramine 4000078 Brompheniramine 1 R06AB01 R06AB01 R06AB01 R06AB01
Dexchlorpheniramine 
4000084
Dexchlorpheniramine 1 R06AB02 R06AB02 R06AB02 R06AB02
Chlorpheniramine 
(=Chlorphenamine) 
4000003
Chlorpheniramine 
(=Chlorphenamine) 1
R06AB04 R06AB04 R06AB04 R06AB04
Pheniramine 4000092 Pheniramine R06AB05 R06AB05 R06AB05 R06AB05
Dexbrompheniramine 
4000083
Dexbrompheniramine 1 R06AB06 R06AB06 R06AB06 R06AB06
Brompheniramine 2 R06AB51 R06AB51 R06AB51 R06AB51
Dexchlorpheniramine 2 R06AB52 R06AB52 R06AB52 R06AB52
Chlorpheniramine 
(=Chlorphenamine) 2 R06AB54 R06AB54 R06AB54 R06AB54
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Dexbrompheniramine 2 R06AB56 R06AB56 R06AB56 R06AB56
Tripelennamine 4000013 Tripelennamine R06AC04 R06AC04 R06AC04 R06AC04
Promethazine 4000010 Promethazine 1 R06AD02 R06AD02 R06AD02 R06AD02
Promethazine 8 
(Hydroxyethylpromethazin 
1) R06AD05 R06AD05 R06AD05 R06AD05
Promethazine 7 
(Dioxopromethazin)
R06AD10 R06AD10 R06AD10 R06AD10
Promethazine 2 R06AD52 R06AD52 R06AD52 R06AD52
Promethazine 9 
(Hydroxyethylpromethazin 
2)
R06AD55 R06AD55 R06AD55 R06AD55
Meclizine 56220005 Meclozine 1 R06AE05  R06AE05  R06AE05  R06AE05  
Cetirizine 4000031 Cetirizin 1 R06AE07 R06AE07 R06AE07 R06AE07
Cetirizin 3 (Enantiomer 
Levocetirizin )
R06AE09 R06AE09 R06AE09 R06AE09
Meclozine 2 R06AE55 R06AE55 R06AE55 R06AE55
Cetirizin 2 R06AE57 R06AE57 R06AE57 R06AE57
Cyproheptadine 4000012 Cyproheptadine 1 R06AX02 R06AX02 R06AX02 R06AX02
Triprolidine 4000099 Triprolidine 1 R06AX07 R06AX07 R06AX07 R06AX07
Azatadine 4000018 Azatadine R06AX09 R06AX09 R06AX09 R06AX09
Astemizole 4000022 Astemizole R06AX11 R06AX11 R06AX11 R06AX11
Loratadine 4000029 Loratadine 1 R06AX13 R06AX13 R06AX13 R06AX13
Loratadine 2 (Enantiomer 
Desloratadin )
R06AX27 R06AX27 R06AX27 R06AX27
Hydroxyzine 2 R06AX32 R06AX32 R06AX32 R06AX32
Triprolidine 2 R06AX57 R06AX57 R06AX57 R06AX57
Promethazine 6 V03AB05 V03AB05 V03AB05 V03AB05
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2014 2013 2012 2011
Schaefer et al. 
(mod.)
Diederich Charlson HRQoL-
Index
Excluded 
diagnoses
B15 B15 B15 B15 0 0 0 1 0
B16 B16 B16 B16 0 0 0 1 0
B17 B17 B17 B17 0 0 0 1 0
B18 B18 B18 B18 0 0 0 1 0
B19 B19 B19 B19 0 0 0 1 0
B20 B20 B20 B20 0 0 1 1 0
B21 B21 B21 B21 0 0 1 1 0
B22 B22 B22 B22 0 0 1 1 0
B23 B23 B23 B23 0 0 1 1 0
B24 B24 B24 B24 0 0 1 1 0
C00 C00 C00 C00 1 1 1 0 0
C01 C01 C01 C01 1 1 1 0 0
C02 C02 C02 C02 1 1 1 0 0
C03 C03 C03 C03 1 1 1 0 0
C04 C04 C04 C04 1 1 1 0 0
C05 C05 C05 C05 1 1 1 0 0
C06 C06 C06 C06 1 1 1 0 0
C07 C07 C07 C07 1 1 1 0 0
C08 C08 C08 C08 1 1 1 0 0
C09 C09 C09 C09 1 1 1 0 0
C10 C10 C10 C10 1 1 1 0 0
C11 C11 C11 C11 1 1 1 0 0
C12 C12 C12 C12 1 1 1 0 0
C13 C13 C13 C13 1 1 1 0 0
C14 C14 C14 C14 1 1 1 0 0
C15 C15 C15 C15 1 1 1 0 0
C16 C16 C16 C16 1 1 1 0 0
C17 C17 C17 C17 1 1 1 0 0
C18 C18 C18 C18 1 1 1 0 0
C19 C19 C19 C19 1 1 1 0 0
C20 C20 C20 C20 1 1 1 0 0
C21 C21 C21 C21 1 1 1 0 0
C22 C22 C22 C22 1 1 1 0 0
C23 C23 C23 C23 1 1 1 0 0
C24 C24 C24 C24 1 1 1 0 0
C25 C25 C25 C25 1 1 1 0 0
C26 C26 C26 C26 1 1 1 0 0
C30 C30 C30 C30 1 1 1 0 0
C31 C31 C31 C31 1 1 1 0 0
C32 C32 C32 C32 1 1 1 0 0
C33 C33 C33 C33 1 1 1 0 0
C34 C34 C34 C34 1 1 1 0 0
C37 C37 C37 C37 1 1 1 0 0
C38 C38 C38 C38 1 1 1 0 0
C39 C39 C39 C39 1 1 1 0 0
C40 C40 C40 C40 1 1 1 0 0
ICD-10-Code  (Source: ICD-10-GM ). 1 = yes, 0 = no
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C41 C41 C41 C41 1 1 1 0 0
C43 C43 C43 C43 1 1 1 0 0
C44 C44 C44 C44 1 1 1 0 0
C45 C45 C45 C45 1 1 1 0 0
C46 C46 C46 C46 1 1 1 0 0
C47 C47 C47 C47 1 1 1 0 0
C48 C48 C48 C48 1 1 1 0 0
C49 C49 C49 C49 1 1 1 0 0
C50 C50 C50 C50 1 1 1 0 0
C51 C51 C51 C51 1 1 1 0 0
C52 C52 C52 C52 1 1 1 0 0
C53 C53 C53 C53 1 1 1 0 0
C54 C54 C54 C54 1 1 1 0 0
C55 C55 C55 C55 1 1 1 0 0
C56 C56 C56 C56 1 1 1 0 0
C57 C57 C57 C57 1 1 1 0 0
C58 C58 C58 C58 1 1 1 0 0
C60 C60 C60 C60 1 1 1 0 0
C61 C61 C61 C61 1 1 1 0 0
C62 C62 C62 C62 1 1 1 0 0
C63 C63 C63 C63 1 1 1 0 0
C64 C64 C64 C64 1 1 1 0 0
C65 C65 C65 C65 1 1 1 0 0
C66 C66 C66 C66 1 1 1 0 0
C67 C67 C67 C67 1 1 1 0 0
C68 C68 C68 C68 1 1 1 0 0
C69 C69 C69 C69 1 1 1 0 0
C70 C70 C70 C70 1 1 1 0 0
C71 C71 C71 C71 1 1 1 0 0
C72 C72 C72 C72 1 1 1 0 0
C73 C73 C73 C73 1 1 1 0 0
C74 C74 C74 C74 1 1 1 0 0
C75 C75 C75 C75 1 1 1 0 0
C76 C76 C76 C76 1 1 1 0 0
C77 C77 C77 C77 1 1 1 0 0
C78 C78 C78 C78 1 1 1 0 0
C79 C79 C79 C79 1 1 1 0 0
C80 C80 C80 C80 1 1 1 0 0
C81 C81 C81 C81 1 1 1 0 0
C82 C82 C82 C82 1 1 1 0 0
C83 C83 C83 C83 1 1 1 0 0
C84 C84 C84 C84 1 1 1 0 0
C85 C85 C85 C85 1 1 1 0 0
C86 C86 C86 C86 1 1 1 0 0
C88 C88 C88 C88 1 1 1 0 0
C90 C90 C90 C90 1 1 1 0 0
C91 C91 C91 C91 1 1 1 0 0
C92 C92 C92 C92 1 1 1 0 0
C93 C93 C93 C93 1 1 1 0 0
C94 C94 C94 C94 1 1 1 0 0
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C95 C95 C95 C95 1 1 1 0 0
C96 C96 C96 C96 1 1 1 0 0
C97 C97 C97 C97 1 1 1 0 0
D00 D00 D00 D00 1 1 1 0 0
D01 D01 D01 D01 1 1 1 0 0
D02 D02 D02 D02 1 1 1 0 0
D03 D03 D03 D03 1 1 1 0 0
D04 D04 D04 D04 1 1 1 0 0
D05 D05 D05 D05 1 1 1 0 0
D06 D06 D06 D06 1 1 1 0 0
D07 D07 D07 D07 1 1 1 0 0
D09 D09 D09 D09 1 1 1 0 0
D37 D37 D37 D37 1 1 1 0 0
D38 D38 D38 D38 1 1 1 0 0
D39 D39 D39 D39 1 1 1 0 0
D40 D40 D40 D40 1 1 1 0 0
D41 D41 D41 D41 1 1 1 0 0
D42 D42 D42 D42 1 1 1 0 0
D43 D43 D43 D43 1 1 1 0 0
D44 D44 D44 D44 1 1 1 0 0
D45 D45 D45 D45 1 1 1 0 0
D46 D46 D46 D46 1 1 1 0 0
D47 D47 D47 D47 1 1 1 0 0
D48 D48 D48 D48 1 1 1 0 0
D50 D50 D50 D50 1 0 0 1 0
D51 D51 D51 D51 1 0 0 1 0
D52 D52 D52 D52 1 0 0 1 0
D53 D53 D53 D53 1 0 0 1 0
D55 D55 D55 D55 1 0 0 1 0
D56 D56 D56 D56 1 0 0 1 0
D57 D57 D57 D57 1 0 0 1 0
D58 D58 D58 D58 1 0 0 1 0
D59.0 D59.0 D59.0 D59.0 1 0 0 1 0
D59.1 D59.1 D59.1 D59.1 1 0 0 1 0
D59.2 D59.2 D59.2 D59.2 1 0 0 1 0
D59.4 D59.4 D59.4 D59.4 1 0 0 1 0
D59.5 D59.5 D59.5 D59.5 1 0 0 1 0
D59.6 D59.6 D59.6 D59.6 1 0 0 1 0
D59.8 D59.8 D59.8 D59.8 1 0 0 1 0
D59.9 D59.9 D59.9 D59.9 1 0 0 1 0
D60.0 D60.0 D60.0 D60.0 1 0 0 1 0
D60.8 D60.8 D60.8 D60.8 1 0 0 1 0
D60.9 D60.9 D60.9 D60.9 1 0 0 1 0
D61 D61 D61 D61 1 0 0 1 0
D63 D63 D63 D63 1 0 0 1 0
D64 D64 D64 D64 1 0 0 1 0
D66 D66 D66 D66 1 0 0 0 0
D67 D67 D67 D67 1 0 0 0 0
D68 D68 D68 D68 1 0 0 0 0
D69 D69 D69 D69 1 0 0 0 0
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E01 E01 E01 E01 1 0 0 1 0
E02 E02 E02 E02 1 0 0 1 0
E03 E03 E03 E03 1 0 0 1 0
E04 E04 E04 E04 1 0 0 1 0
E05 E05 E05 E05 1 0 0 1 0
E06.1 E06.1 E06.1 E06.1 1 0 0 1 0
E06.2 E06.2 E06.2 E06.2 1 0 0 1 0
E06.3 E06.3 E06.3 E06.3 1 0 0 1 0
E06.5 E06.5 E06.5 E06.5 1 0 0 1 0
E06.9 E06.9 E06.9 E06.9 1 0 0 1 0
E07 E07 E07 E07 1 0 0 1 0
E10.0 E10.0 E10.0 E10.0 1 1 1 1 0
E10.1 E10.1 E10.1 E10.1 1 1 1 1 0
E10.2 E10.2 E10.2 E10.2 1 1 1 1 0
E10.3 E10.3 E10.3 E10.3 1 1 1 1 0
E10.4 E10.4 E10.4 E10.4 1 1 1 1 0
E10.5 E10.5 E10.5 E10.5 1 1 1 1 0
E10.6 E10.6 E10.6 E10.6 1 1 1 1 0
E10.7 E10.7 E10.7 E10.7 1 1 1 1 0
E10.8 E10.8 E10.8 E10.8 1 1 1 1 0
E10.9 E10.9 E10.9 E10.9 1 1 1 1 0
E11.0 E11.0 E11.0 E11.0 1 1 1 1 0
E11.1 E11.1 E11.1 E11.1 1 1 1 1 0
E11.2 E11.2 E11.2 E11.2 1 1 1 1 0
E11.3 E11.3 E11.3 E11.3 1 1 1 1 0
E11.4 E11.4 E11.4 E11.4 1 1 1 1 0
E11.5 E11.5 E11.5 E11.5 1 1 1 1 0
E11.6 E11.6 E11.6 E11.6 1 1 1 1 0
E11.7 E11.7 E11.7 E11.7 1 1 1 1 0
E11.8 E11.8 E11.8 E11.8 1 1 1 1 0
E11.9 E11.9 E11.9 E11.9 1 1 1 1 0
E12.0 E12.0 E12.0 E12.0 1 1 1 1 0
E12.1 E12.1 E12.1 E12.1 1 1 1 1 0
E12.2 E12.2 E12.2 E12.2 1 1 1 1 0
E12.3 E12.3 E12.3 E12.3 1 1 1 1 0
E12.4 E12.4 E12.4 E12.4 1 1 1 1 0
E12.5 E12.5 E12.5 E12.5 1 1 1 1 0
E12.6 E12.6 E12.6 E12.6 1 1 1 1 0
E12.7 E12.7 E12.7 E12.7 1 1 1 1 0
E12.8 E12.8 E12.8 E12.8 1 1 1 1 0
E12.9 E12.9 E12.9 E12.9 1 1 1 1 0
E13.0 E13.0 E13.0 E13.0 1 1 1 1 0
E13.1 E13.1 E13.1 E13.1 1 1 1 1 0
E13.2 E13.2 E13.2 E13.2 1 1 1 1 0
E13.3 E13.3 E13.3 E13.3 1 1 1 1 0
E13.4 E13.4 E13.4 E13.4 1 1 1 1 0
E13.5 E13.5 E13.5 E13.5 1 1 1 1 0
E13.6 E13.6 E13.6 E13.6 1 1 1 1 0
E13.7 E13.7 E13.7 E13.7 1 1 1 1 0
E13.8 E13.8 E13.8 E13.8 1 1 1 1 0
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E13.9 E13.9 E13.9 E13.9 1 1 1 1 0
E14.0 E14.0 E14.0 E14.0 1 1 1 1 0
E14.1 E14.1 E14.1 E14.1 1 1 1 1 0
E14.2 E14.2 E14.2 E14.2 1 1 1 1 0
E14.3 E14.3 E14.3 E14.3 1 1 1 1 0
E14.4 E14.4 E14.4 E14.4 1 1 1 1 0
E14.5 E14.5 E14.5 E14.5 1 1 1 1 0
E14.6 E14.6 E14.6 E14.6 1 1 1 1 0
E14.7 E14.7 E14.7 E14.7 1 1 1 1 0
E14.8 E14.8 E14.8 E14.8 1 1 1 1 0
E14.9 E14.9 E14.9 E14.9 1 1 1 1 0
E16.0 E16.0 E16.0 E16.0 1 1 0 1 0
E16.1 E16.1 E16.1 E16.1 0 1 0 1 0
E16.2 E16.2 E16.2 E16.2 0 1 0 1 0
E16.3 E16.3 E16.3 E16.3 0 1 0 1 0
E16.4 E16.4 E16.4 E16.4 0 1 0 1 0
E16.5 E16.5 E16.5 E16.5 0 1 0 1 0
E16.6 E16.6 E16.6 E16.6 0 1 0 1 0
E16.7 E16.7 E16.7 E16.7 0 1 0 1 0
E16.8 E16.8 E16.8 E16.8 0 1 0 1 0
E16.9 E16.9 E16.9 E16.9 0 1 0 1 0
E66 E66 E66 E66 1 0 0 0 0
E73 E73 E73 E73 1 0 0 0 0
E78 E78 E78 E78 1 0 0 0 0
E79 E79 E79 E79 1 0 0 0 0
F00 F00 F00 F00 0 0 0 0 1
F01 F01 F01 F01 0 0 0 0 1
F02 F02 F02 F02 0 0 0 0 1
F03 F03 F03 F03 0 0 0 0 1
F05.1 F05.1 F05.1 F05.1 0 0 0 0 1
F10 F10 F10 F10 1 0 0 0 0
F13 F13 F13 F13 1 0 0 0 0
F17 F17 F17 F17 1 0 0 0 0
F20 F20 F20 F20 0 0 0 1 0
F21 F21 F21 F21 0 0 0 1 0
F22 F22 F22 F22 0 0 0 1 0
F23 F23 F23 F23 0 0 0 1 0
F24 F24 F24 F24 0 0 0 1 0
F25 F25 F25 F25 0 0 0 1 0
F28 F28 F28 F28 0 0 0 1 0
F29 F29 F29 F29 0 0 0 1 0
F30 F30 F30 F30 0 0 0 1 0
F31 F31 F31 F31 0 0 0 1 0
F32 F32 F32 F32 1 1 0 1 0
F33 F33 F33 F33 1 1 0 1 0
F34 F34 F34 F34 0 0 0 1 0
F38 F38 F38 F38 0 0 0 1 0
F39 F39 F39 F39 0 0 0 1 0
F40 F40 F40 F40 1 0 0 1 0
F41 F41 F41 F41 1 0 0 1 0
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F45 F45 F45 F45 1 0 0 0 0
F51 F51 F51 F51 1 0 0 0 0
F52 F52 F52 F52 1 0 0 0 0
G20 G20 G20 G20 1 0 0 1 0
G21 G21 G21 G21 1 0 0 1 0
G22 G22 G22 G22 1 0 0 1 0
G30 G30 G30 G30 0 0 0 0 1
G31 G31 G31 G31 0 0 0 0 1
G35 G35 G35 G35 0 0 0 1 0
G40 G40 G40 G40 1 0 0 1 0
G41 G41 G41 G41 1 0 0 1 0
G43 G43 G43 G43 1 0 0 1 0
G44 G44 G44 G44 1 0 0 1 0
G45 G45 G45 G45 1 1 1 1 0
G47 G47 G47 G47 1 0 0 0 0
G50 G50 G50 G50 1 0 0 0 0
G51 G51 G51 G51 1 0 0 0 0
G52 G52 G52 G52 1 0 0 0 0
G53 G53 G53 G53 1 0 0 0 0
G54 G54 G54 G54 1 0 0 0 0
G55 G55 G55 G55 1 0 0 0 0
G56 G56 G56 G56 1 0 0 0 0
G57 G57 G57 G57 1 0 0 0 0
G58 G58 G58 G58 1 0 0 0 0
G59 G59 G59 G59 1 0 0 0 0
G60 G60 G60 G60 1 0 0 0 0
G61 G61 G61 G61 1 0 0 0 0
G62 G62 G62 G62 1 0 0 0 0
G63 G63 G63 G63 1 0 0 0 0
G64 G64 G64 G64 1 0 0 0 0
G80.0 G80.0 G80.0 G80.0 0 0 1 1 0
G80.1 G80.1 G80.1 G80.1 0 0 1 1 0
G80.2 G80.2 G80.2 G80.2 0 0 1 1 0
G81 G81 G81 G81 0 0 1 1 0
G82 G82 G82 G82 0 0 1 1 0
G83.0 G83.0 G83.0 G83.0 0 0 1 1 0
H01.1 H01.1 H01.1 H01.1 1 0 0 0 0
H17 H17 H17 H17 1 1 0 1 0
H18 H18 H18 H18 1 1 0 1 0
H25 H25 H25 H25 1 1 0 1 0
H26 H26 H26 H26 1 1 0 1 0
H27 H27 H27 H27 1 1 0 1 0
H28 H28 H28 H28 1 1 0 1 0
H31 H31 H31 H31 1 1 0 1 0
H33 H33 H33 H33 1 0 0 1 0
H34.1 H34.1 H34.1 H34.1 1 1 0 1 0
H34.2 H34.2 H34.2 H34.2 1 1 0 1 0
H34.8 H34.8 H34.8 H34.8 1 1 0 1 0
H34.9 H34.9 H34.9 H34.9 1 1 0 1 0
H35 H35 H35 H35 1 1 0 1 0
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H36 H36 H36 H36 1 1 0 1 0
H40 H40 H40 H40 1 1 0 1 0
H43 H43 H43 H43 1 1 0 1 0
H47 H47 H47 H47 1 1 0 1 0
H54 H54 H54 H54 1 1 0 1 0
H81 H81 H81 H81 1 0 0 0 0
H82 H82 H82 H82 1 0 0 0 0
H90 H90 H90 H90 1 1 0 0 0
H91.0 H91.0 H91.0 H91.0 1 1 0 0 0
H91.1 H91.1 H91.1 H91.1 1 1 0 0 0
H91.3 H91.3 H91.3 H91.3 1 1 0 0 0
H91.8 H91.8 H91.8 H91.8 1 1 0 0 0
H91.9 H91.9 H91.9 H91.9 1 1 0 0 0
I10 I10 I10 I10 1 1 0 1 0
I11 I11 I11 I11 1 1 0 1 0
I12 I12 I12 I12 1 1 0 1 0
I13 I13 I13 I13 1 1 0 1 0
I15 I15 I15 I15 1 1 0 1 0
I20 I20 I20 I20 1 1 0 1 0
I21 I21 I21 I21 1 1 1 1 0
I22 I22 I22 I22 1 0 0 1 0
I23 I23 I23 I23 1 0 0 1 0
I24 I24 I24 I24 1 0 0 1 0
I25 I25 I25 I25 1 1 0 1 0
I26 I26 I26 I26 1 0 0 0 0
I34 I34 I34 I34 1 0 0 0 0
I35 I35 I35 I35 1 0 0 0 0
I36 I36 I36 I36 1 0 0 0 0
I37 I37 I37 I37 1 0 0 0 0
I44 I44 I44 I44 1 0 0 1 0
I45 I45 I45 I45 1 0 0 1 0
I46.0 I46.0 I46.0 I46.0 1 0 0 1 0
I46.9 I46.9 I46.9 I46.9 1 0 0 1 0
I47 I47 I47 I47 1 0 0 1 0
I48 I48 I48 I48 1 0 0 1 0
I49.1 I49.1 I49.1 I49.1 1 0 0 1 0
I49.2 I49.2 I49.2 I49.2 1 0 0 1 0
I49.3 I49.3 I49.3 I49.3 1 0 0 1 0
I49.4 I49.4 I49.4 I49.4 1 0 0 1 0
I49.5 I49.5 I49.5 I49.5 1 0 0 1 0
I49.8 I49.8 I49.8 I49.8 1 0 0 1 0
I49.9 I49.9 I49.9 I49.9 1 0 0 1 0
I50 I50 I50 I50 1 1 1 1 0
I60 I60 I60 I60 1 1 1 1 0
I61 I61 I61 I61 1 1 1 1 0
I62 I62 I62 I62 1 1 1 1 0
I63 I63 I63 I63 1 1 1 1 0
I64 I64 I64 I64 1 1 1 1 0
I65 I65 I65 I65 1 1 1 1 0
I66 I66 I66 I66 1 1 1 1 0
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I67.0 I67.0 I67.0 I67.0 0 1 0 0 0
I67.2 I67.2 I67.2 I67.2 1 1 1 1 0
I67.4 I67.4 I67.4 I67.4 1 1 0 1 0
I67.8 I67.8 I67.8 I67.8 0 1 0 0 0
I67.9 I67.9 I67.9 I67.9 0 1 0 0 0
I69 I69 I69 I69 1 1 1 1 0
I70 I70 I70 I70 1 1 1 1 0
I71 I71 I71 I71 1 1 1 1 0
I72 I72 I72 I72 1 1 1 1 0
I73.9 I73.9 I73.9 I73.9 1 1 1 1 0
I80 I80 I80 I80 1 0 0 0 0
I83 I83 I83 I83 1 0 0 0 0
I87.0 I87.0 I87.0 I87.0 1 0 0 0 0
I87.2 I87.2 I87.2 I87.2 1 0 0 0 0
I95 I95 I95 I95 1 0 0 0 0
J30 J30 J30 J30 1 0 0 0 0
J40 J40 J40 J40 1 1 1 0 0
J41 J41 J41 J41 1 1 1 1 0
J42 J42 J42 J42 1 1 1 1 0
J43 J43 J43 J43 1 1 1 1 0
J44 J44 J44 J44 1 1 1 1 0
J45 J45 J45 J45 1 1 1 1 0
J47 J47 J47 J47 1 1 1 1 0
K21 K21 K21 K21 1 0 0 1 0
K25.4 K25.4 K25.4 K25.4 1 0 1 1 0
K25.5 K25.5 K25.5 K25.5 1 0 1 1 0
K25.6 K25.6 K25.6 K25.6 1 0 1 1 0
K25.7 K25.7 K25.7 K25.7 1 0 1 1 0
K25.9 K25.9 K25.9 K25.9 1 0 1 1 0
K26.4 K26.4 K26.4 K26.4 1 0 1 1 0
K26.5 K26.5 K26.5 K26.5 1 0 1 1 0
K26.6 K26.6 K26.6 K26.6 1 0 1 1 0
K26.7 K26.7 K26.7 K26.7 1 0 1 1 0
K26.9 K26.9 K26.9 K26.9 1 0 1 1 0
K27.4 K27.4 K27.4 K27.4 1 0 1 1 0
K27.5 K27.5 K27.5 K27.5 1 0 1 1 0
K27.6 K27.6 K27.6 K27.6 1 0 1 1 0
K27.7 K27.7 K27.7 K27.7 1 0 1 1 0
K27.9 K27.9 K27.9 K27.9 1 0 1 1 0
K28.4 K28.4 K28.4 K28.4 1 0 1 1 0
K28.5 K28.5 K28.5 K28.5 1 0 1 1 0
K28.6 K28.6 K28.6 K28.6 1 0 1 1 0
K28.7 K28.7 K28.7 K28.7 1 0 1 1 0
K28.9 K28.9 K28.9 K28.9 1 0 1 1 0
K29.2 K29.2 K29.2 K29.2 1 0 1 1 0
K29.3 K29.3 K29.3 K29.3 1 0 1 1 0
K29.4 K29.4 K29.4 K29.4 1 0 1 1 0
K29.5 K29.5 K29.5 K29.5 1 0 1 1 0
K29.6 K29.6 K29.6 K29.6 1 0 1 1 0
K29.7 K29.7 K29.7 K29.7 1 0 1 1 0
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K29.8 K29.8 K29.8 K29.8 1 0 1 1 0
K29.9 K29.9 K29.9 K29.9 1 0 1 1 0
K52.2 K52.2 K52.2 K52.2 1 0 0 0 0
K57 K57 K57 K57 1 0 0 0 0
K58 K58 K58 K58 1 0 0 0 0
K64 K64 I84 I84 1 0 0 0 0
K70.0 K70.0 K70.0 K70.0 1 0 1 1 0
K70.1 K70.1 K70.1 K70.1 1 0 1 1 0
K70.2 K70.2 K70.2 K70.2 1 0 0 1 0
K70.3 K70.3 K70.3 K70.3 1 0 0 1 0
K70.4 K70.4 K70.4 K70.4 1 0 1 1 0
K70.5 K70.5 K70.5 K70.5 1 0 0 1 0
K70.6 K70.6 K70.6 K70.6 1 0 0 1 0
K70.7 K70.7 K70.7 K70.7 1 0 0 1 0
K70.8 K70.8 K70.8 K70.8 1 0 0 1 0
K70.9 K70.9 K70.9 K70.9 1 0 1 1 0
K71.0 K71.0 K71.0 K71.0 0 0 1 0 0
K71.1 K71.1 K71.1 K71.1 0 0 1 0 0
K71.2 K71.2 K71.2 K71.2 0 0 1 0 0
K71.3 K71.3 K71.3 K71.3 1 0 0 1 0
K71.4 K71.4 K71.4 K71.4 1 0 0 1 0
K71.5 K71.5 K71.5 K71.5 1 0 0 1 0
K71.6 K71.6 K71.6 K71.6 0 0 1 0 0
K71.7 K71.7 K71.7 K71.7 1 0 0 1 0
K71.8 K71.8 K71.8 K71.8 0 0 1 0 0
K72.0 K72.0 K72.0 K72.0 0 0 1 0 0
K72.1 K72.1 K72.1 K72.1 1 0 1 1 0
K72.2 K72.2 K72.2 K72.2 0 0 1 0 0
K72.3 K72.3 K72.3 K72.3 0 0 1 0 0
K72.4 K72.4 K72.4 K72.4 0 0 1 0 0
K72.5 K72.5 K72.5 K72.5 0 0 1 0 0
K72.6 K72.6 K72.6 K72.6 0 0 1 0 0
K72.7 K72.7 K72.7 K72.7 1 0 1 1 0
K72.8 K72.8 K72.8 K72.8 0 0 1 0 0
K72.9 K72.9 K72.9 K72.9 1 0 1 1 0
K73 K73 K73 K73 1 0 1 1 0
K74 K74 K74 K74 1 0 1 1 0
K75.0 K75.0 K75.0 K75.0 0 0 1 0 0
K75.1 K75.1 K75.1 K75.1 0 0 1 0 0
K75.2 K75.2 K75.2 K75.2 0 0 1 0 0
K75.3 K75.3 K75.3 K75.3 0 0 1 0 0
K75.4 K75.4 K75.4 K75.4 0 0 1 0 0
K75.8 K75.8 K75.8 K75.8 0 0 1 0 0
K75.9 K75.9 K75.9 K75.9 0 0 1 0 0
K76.0 K76.0 K76.0 K76.0 0 0 1 1 0
K76.1 K76.1 K76.1 K76.1 0 0 1 1 0
K76.2 K76.2 K76.2 K76.2 1 0 0 1 0
K76.3 K76.3 K76.3 K76.3 1 0 0 1 0
K76.4 K76.4 K76.4 K76.4 1 0 0 1 0
K76.5 K76.5 K76.5 K76.5 1 0 0 1 0
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K76.6 K76.6 K76.6 K76.6 1 0 0 1 0
K76.7 K76.7 K76.7 K76.7 1 0 0 1 0
K76.8 K76.8 K76.8 K76.8 1 0 0 1 0
K76.9 K76.9 K76.9 K76.9 1 0 0 1 0
K77 K77 K77 K77 0 0 1 0 0
K80 K80 K80 K80 1 0 0 1 0
K81.1 K81.1 K81.1 K81.1 1 0 0 1 0
K90.0 K90.0 K90.0 K90.0 1 0 0 0 0
L23 L23 L23 L23 1 0 0 0 0
L27.2 L27.2 L27.2 L27.2 1 0 0 0 0
L40 L40 L40 L40 1 0 0 0 0
L56.4 L56.4 L56.4 L56.4 1 0 0 0 0
M05 M05 M05 M05 1 1 0 1 0
M06 M06 M06 M06 1 1 0 1 0
M07 M07 M07 M07 1 1 0 1 0
M10 M10 M10 M10 1 0 0 0 0
M15 M15 M15 M15 1 1 0 1 0
M16 M16 M16 M16 1 1 0 1 0
M17 M17 M17 M17 1 1 0 1 0
M18 M18 M18 M18 1 1 0 1 0
M19 M19 M19 M19 1 1 0 1 0
M30 M30 M30 M30 1 0 1 1 0
M31 M31 M31 M31 1 0 1 1 0
M32 M32 M32 M32 1 0 1 1 0
M33 M33 M33 M33 1 0 1 1 0
M34 M34 M34 M34 1 0 1 1 0
M35 M35 M35 M35 1 0 1 1 0
M36 M36 M36 M36 1 0 1 1 0
M40 M40 M40 M40 1 0 0 1 0
M41 M41 M41 M41 1 0 0 1 0
M42 M42 M42 M42 1 0 0 1 0
M43 M43 M43 M43 1 0 0 1 0
M45 M45 M45 M45 1 0 0 1 0
M47 M47 M47 M47 1 0 0 1 0
M48.0 M48.0 M48.0 M48.0 1 0 0 1 0
M48.1 M48.1 M48.1 M48.1 1 0 0 1 0
M48.2 M48.2 M48.2 M48.2 1 0 0 1 0
M48.5 M48.5 M48.5 M48.5 1 0 0 1 0
M48.8 M48.8 M48.8 M48.8 1 0 0 1 0
M48.9 M48.9 M48.9 M48.9 1 0 0 1 0
M50 M50 M50 M50 1 0 0 1 0
M51 M51 M51 M51 1 0 0 1 0
M53 M53 M53 M53 1 0 0 1 0
M54 M54 M54 M54 1 0 0 1 0
M79.0 M79.0 M79.0 M79.0 1 1 0 0 0
M80 M80 M80 M80 1 1 0 0 0
M81 M81 M81 M81 1 1 0 0 0
M82 M82 M82 M82 1 1 0 0 0
N00 N00 N00 N00 1 1 1 0 0
N01 N01 N01 N01 1 1 1 0 0
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N02 N02 N02 N02 1 1 1 0 0
N03 N03 N03 N03 1 1 1 0 0
N04 N04 N04 N04 1 1 1 0 0
N05 N05 N05 N05 1 1 1 0 0
N06 N06 N06 N06 1 1 1 0 0
N07 N07 N07 N07 1 1 1 0 0
N08 N08 N08 N08 1 1 1 0 0
N18 N18 N18 N18 1 1 1 0 0
N19 N19 N19 N19 1 1 1 0 0
N20 N20 N20 N20 1 0 0 0 0
N25 N25 N25 N25 1 1 1 0 0
N26 N26 N26 N26 1 1 1 0 0
N27 N27 N27 N27 1 1 1 0 0
N28 N28 N28 N28 1 1 1 0 0
N29 N29 N29 N29 1 1 1 0 0
N39.3 N39.3 N39.3 N39.3 1 0 0 0 0
N39.4 N39.4 N39.4 N39.4 1 0 0 0 0
N40 N40 N40 N40 1 0 0 0 0
N48.4 N48.4 N48.4 N48.4 1 0 0 0 0
N81 N81 N81 N81 1 0 0 0 0
N84 N84 N84 N84 1 0 0 0 0
N85 N85 N85 N85 1 0 0 0 0
N86 N86 N86 N86 1 0 0 0 0
N87 N87 N87 N87 1 0 0 0 0
N88 N88 N88 N88 1 0 0 0 0
N89 N89 N89 N89 1 0 0 0 0
N90 N90 N90 N90 1 0 0 0 0
N93 N93 N93 N93 1 0 0 0 0
N95 N95 N95 N95 1 0 0 0 0
R00 R00 R00 R00 1 0 0 1 0
R03.1 R03.1 R03.1 R03.1 1 0 0 0 0
R32 R32 R32 R32 1 0 0 0 0
R42 R42 R42 R42 1 0 0 0 0
R51 R51 R51 R51 1 0 0 1 0
R54 R54 R54 R54 0 0 0 0 1
T78.1 T78.1 T78.1 T78.1 1 0 0 0 0
T78.4 T78.4 T78.4 T78.4 1 0 0 0 0
T88.7 T88.7 T88.7 T88.7 1 0 0 0 0
U85 U85 U85 U85 0 0 1 0 0
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CRT participants
(n=505)
Persons insured by
TK in 2012 
(n=8,109,215)
No. of participants
included in analyses
(n=502)
No. of persons
insured by TK and
included in analyses
(n=592,456)
Excluded (n=3)
- Age <60 years (n=3) 
Excluded (n=7,516,759)
- Age <60 years (n=6,572,610)
- Not continuously insured by TK between
01/12 and 12/14 and/or no primary care 
contact in 2012 (n=158,688)
- <3 chronic diseases (n=268,319)
- <5 chronic medications (n=454,758)
- Dementia diagnosis (n =27,115)
- Under legal guardianship (n=35,269)
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Additional file 5: Univariate Analyses: Association between predictor variables and combined outcome in claims data 
 
combined outcome reached  
after 6 months 
combined outcome reached  
after 9 months 
combined outcome reached  
after 24 months 
  Yes 
(n = 
192357) 
No 
(n = 
400099) 
Total 
(n = 
592456) 
 
Yes 
(n = 
244190) 
No 
(n = 
348266) 
Total 
(n = 
592456) 
 
Yes 
(n = 
387951) 
No 
(n = 
204505) 
Total 
(n = 
592456) 
 
  Mean 
(SD) 
Mean 
(SD) 
Mean 
(SD) 
 p-value Mean 
(SD) 
Mean 
(SD) 
Mean 
(SD) 
p-value  Mean 
(SD) 
Mean 
(SD) 
Mean 
(SD) 
p-value 
Age 72.2 (7.3) 70.8 (6.9) 71.3 (7.1) <0.001 72.1 (7.3) 70.7 (6.9) 71.3 (7.1) <0.001 71.8 (7.2) 70.2 (6.7) 71.3 (7.1) <0.001 
Disease count 10.5 (4.0) 9.3 (3.6) 9.7 (3.8) <0.001 10.4 (3.9) 9.2 (3.5) 9.7 (3.8) <0.001 10.2 (3.9) 8.8 (3.4) 9.7 (3.8) <0.001 
CCI 3.4 (2.8) 2.8 (2.4) 3.0 (2.5) <0.001 3.4 (2.7) 2.8 (2.4) 3.0 (2.5) <0.001 3.2 (2.7) 2.6 (2.3) 3.0 (2.5) <0.001 
No. of specific chronic 
diseases (Diederichs) 
4.7 (2.1) 4.1 (1.9) 4.3 (2.0) <0.001 4.7 (2.1) 4.1 (1.9) 4.3 (2.0) <0.001 4.6 (2.0) 3.9 (1.8) 4.3 (2.0) <0.001 
No. of PIM (EU-PIM) 1.3 (1.2) 1.1 (1.1) 1.1 (1.2) <0.001 1.3 (1.2) 1.1 (1.1) 1.1 (1.2) <0.001 1.2 (1.2) 1.0 (1.0) 1.1 (1.1) <0.001 
ADS 1.2 (1.6) 0.9 (1.4) 1.0 (1.5) <0.001 1.2 (1.6) 0.9 (1.3) 1.0 (1.5) <0.001 1.1 (1.5) 0.8 (1.3) 1.0 (1.5) <0.001 
DBI 0.9 (1.2) 0.7 (1.0) 0.8 (1.0) <0.001 0.9 (1.1) 0.7 (0.9) 0.8 (1.0) <0.001 0.8 (1.1) 0.6 (0.9) 0.8 (1.0) <0.001 
Number of involved 
physicians 
11.0 (5.6) 9.4 (5.0) 10.0 (5.3) <0.001 10.9 (5.6) 9.3 (4.9) 10.0 (5.3) <0.001 10.6 (5.4) 8.8 (4.7) 10.0 (5.3) <0.001 
Abbreviations: ACh burden – Anticholinergic drug burden, ADS – Anticholinergic Drug Scale, CCI - Charlson Comorbidity Index, DBI – Drug 
Burden Index, PIM – Potentially Inappropriate Medication. 
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combined outcome reached  
after 6 months 
combined outcome reached  
after 9 months 
combined outcome reached  
after 24 months 
  Yes 
(n = 
192357) 
No 
(n = 
400099) 
Total 
(n = 
592456) 
 
Yes 
(n = 
244190) 
No 
(n = 
348266) 
Total 
(n = 
592456) 
 
Yes 
(n = 
387951) 
No 
(n = 
204505) 
Total 
(n = 
592456) 
 
 
n (%) n (%) n (%)  p-value n (%) n (%) n (%)   p-value n (%) n (%) n (%)   p-value 
Sex Female 90924 
(47.3%) 
182079 
(45.5%) 
273003 
(46.1%) 
 114859 
(47.0%) 
158144 
(45.4%) 
273003 
(46.1%) 
 180222 
(46.5%) 
92781 
(45.4%) 
273003 
(46.1%) 
 
Male 101433 
(52.7%) 
218020 
(54.5%) 
319453 
(53.9%) 
<0.001 129331 
(53.0%) 
190122 
(54.6%) 
319453 
(53.9%) 
<0.001 207729 
(53.5%) 
111724 
(54.6%) 
319453 
(53.9%) 
<0.001 
Previous 
hospitalis
ation 
No 107627 
(56%) 
289845 
(72.4%) 
397472 
(67.1%) 
  141326 
(57.9%) 
256146 
(73.5%) 
397472 
(67.1%) 
  240676 
(62%) 
156796 
(76.7%) 
397472 
(67.1%) 
  
yes 84730 
(44%) 
110254 
(27.6%) 
194984 
(32.9%) 
<0.001 102864 
(42.1%) 
92120 
(26.5%) 
194984 
(32.9%) 
<0.001 147275 
(38%) 
47709 
(23.3%) 
194984 
(32.9%) 
<0.001 
Previous 
falls 
No 103734 
(53.9%) 
325335 
(81.3%) 
429069 
(72.4%) 
  142477 
(58.3%) 
286592 
(82.3%) 
429069 
(72.4%) 
  255691 
(65.9%) 
173378 
(84.8%) 
429069 
(72.4%) 
  
 yes 88623 
(46.1%) 
74764 
(18.7%) 
163387 
(27.6%) 
<0.001 101713 
(41.7%) 
61674 
(17.7%) 
163387 
(27.6%) 
<0.001 132260 
(34.1%) 
31127 
(15.2%) 
163387 
(27.6%) 
<0.001 
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Additional file 6: Univariate analyses 
Table A6.1: Association between predictor variables and EQ5D-3L (Pearson 
Correlation)  
Predictor variable EQ5D-3L (T1) 
Core predictors 
 Age 
 Disease count  
 Charlson Comorbidity Index (CCI) 
 No. of specific chronic diseases (Diederichs) 
 No. of drugs  
 No. of PIM (EU-PIM) 
 ACh burden (ADS) 
 Mod. Drug Burden Index  
 No. of involved physicians  
Additional predictors  
 No. of persons living in household  
 CASMIN  
 Alcohol intake (AUDIT C)  
 Body Mass Index 
 MAI  
 CIRS sum score  
 CIRS, no. of organ systems 
 HRQoL-CI, mental 
 HRQoL-CI, physical  
 Depressive Symptoms (GDS) 
 
-0.09 
-0.24 
-0.07 
-0.19 
-0.26 
-0.18 
-0.16 
-0.20 
-0.06 
 
0.04 
0.09 
0.13 
-0.15 
-0.24 
-0.27 
-0.22 
-0.24 
-0.20 
-0.52 
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 EQ5D-3L (Baseline)  0.68 
  
Abbreviations: ACh burden – Anticholinergic drug burden, ADS – Anticholinergic 
Drug Scale, AUDIT - Alcohol Use Disorders Identification Test (WHO), CASMIN - 
Comparative Analysis of Social Mobility in Industrial Nations, CCI - Charlson 
Comorbidity Index, CIRS – Cumulative Illness Rating Scale, GDS – Geriatric 
Depression Scale, HRQoL – Health-Related Quality of Life, HRQoL-CI – Health-
Related Quality of Life Comorbidity Index, MAI – Medication Appropriateness Index, 
PIM – Potentially Inappropriate Medication. 
 
Table A6.2: Association between predictor variables and EQ5D-3L (T-Test) 
Predictor variable Mean (SD) Mean (SD) p-value 
Core predictors  
 Sex (female / male)  
 Previous hospitalisation (yes / no)  
 Previous falls (yes/no) 
67.7 (25.77) 
71.2 (26.76) 
65.9 (25.28) 
78.5 (22.97) 
73.3 (24.67) 
74.3 (24.76) 
<0.001 
0.531 
0.011 
Additional predictors 
 Smoker (yes / no) 74.1 (25.81) 73.1 (25.07) 0.807 
Abbreviations: SD – Standard Deviation 
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